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Hyponatremia, a condition of low serum concentrations of sodium, shares an 
intertwined and often paradoxical relationship with thiazide diuretics and 
osteoporosis. In retrospective studies, thiazides have been shown to protect against 
osteoporosis-related fractures, but also to cause hyponatremia which is associated 
with a higher risk of falling. In recent years, evidence has been found of an 
association between hyponatremia and osteoporosis in epidemiological and basal in 
vitro studies. Further research is needed to determine three aspects; who will benefit 
from thiazides in terms of fracture risk, why this is the case, and who are running an 
unnecessary risk of thiazide-induced hyponatremia when commencing therapy, 
predisposing to fractures.
The aim of this thesis was to investigate the role of hyponatremia in Danish 
osteoporosis patients, to investigate possible age groups that may benefit from 
thiazide therapy on fracture risk, and to examine the effect of hyponatremia on 
mortality, hospitalization burden and readmission risk.
This thesis is based on six retrospective epidemiological studies using Danish and 
Belgian data of regional and national origins, and one systematic review and meta-
analysis reviewing clinical trials of thiazide use on bone mineral density and 
electrolyte metabolism.
Hyponatremia was found to be associated with a higher risk of WHO-defined 
osteoporosis in the hip region, with a dose-response relationship between lower 
serum sodium and lower BMC and BMD in all regions of interest in the hip region. 
In fracture-prone areas of the hip, chronic mild hyponatremia ([Na+] 130-137 
mmol/L) was associated with worse progression of osteoporosis compared to 
normonatremia, despite a worse offset with lower BMD at baseline. In the meta-
analysis, thiazide therapy was found to provide borderline significantly positive 
effects on BMD and a potentially beneficial pattern of altered electrolyte 
metabolism, i.e. lower urinary calcium, higher serum calcium and borderline 
significantly lower PTH. Compared to non-users, commencing thiazide therapy was 
associated with an increased weekly fracture risk beyond an originally higher pre-
commencement risk during the first 42 weeks of therapy, but then progressively 
lower weekly risk from week 43 onwards. Between ages 50 and 63 years, 
commencing thiazide therapy was found to have 10-year risks of fractures 
comparable to non-users, while commencing therapy hereafter was associated with 
increased 10-year risks. Discontinuing therapy after age 73 was found to be 
beneficial to 10-year fracture risk. Lower serum sodium during hospitalizations was 
associated with longer LoS and greater CoS, but with comparable readmission risk. 
Neither serum sodium nor thiazide use was found to be a relatively strong predictor 
of 5-year mortality or 3-year incident immobility in older men.
4
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Prospective studies of hyponatremia in relation to bone metabolism, i.e. by 
observing biochemical markers of bone metabolism, are warranted to further 
investigate the causal mechanisms. More clinical trials on the effects of thiazides on 
bone metabolism and postural balance are needed to segment users who may benefit 




Hyponatriæmi er en tilstand med lav serumkoncentration af natrium i kroppen. 
Tilstanden kan være indbyrdes forbundet med både vanddrivende medicin af typen 
thiazid, og osteoporose, på en ofte paradoksal måde. Thiazid er vist at beskytte mod 
frakturer i retrospektive studier, men kan samtidig forårsage hyponatriæmi, som er 
associeret med højere risiko for fald. I de senere år er der også fundet evidens for en 
association mellem hyponatriæmi og osteoporose i både epidemiologiske og 
cellulære studier. Yderligere forskning er nødvendig for at adskille dem, der kan 
drage fordel af thiazid-behandling på frakturrisiko, og dem, som løber en risiko for 
thiazid-relateret hyponatriæmi og de mulige konsekvenser heraf.
Formålet med denne afhandling var at undersøge hyponatriæmis rolle blandt danske 
osteoporosepatienter, at undersøge hvilke aldersgrupper, der muligvis kan drage 
fordel af thiazid-behandling på frakturrisiko, og at undersøge hyponatriæmis rolle i 
indlæggelses- og genindlæggelsesbyrden i Danmark.
Denne afhandling udgøres af seks retrospektive epidemiologiske studier af danske 
data af både regional og national karakter, tillige af belgiske regionale data, samt ét 
systematisk review med meta-analyse, som gennemgår kliniske studier om thiazid-
medicins rolle i knogle- og elektrolytmetabolisme.
Hyponatriæmi blev fundet at være associeret med en højere risiko for WHO-
defineret osteoporose i hoften, med et dosis-respons forhold mellem lavere natrium 
og lavere knoglemasse og –tæthed i hofteregionen. Kronisk mild hyponatriæmi 
([Na+] 130-137 mmol/L) blev fundet at være associeret med værre forløb af 
osteoporose i frakturrelaterede regioner i hoften sammenlignet med normal 
natriumkoncentration, trods et værre udgangspunkt med lavere knogletæthed. I 
meta-analysen blev thiazidbehandling fundet at have en nær-signifikant positiv 
effekt på knogletæthed, og at forårsage et muligt gunstigt mønster af ændret 
elektrolytmetabolisme via lavere urinudskillelse af kalk, højere kalk i blodet og 
nærsignifikant lavere niveauer af parathyroideahormon i blodet. Påbegyndelse af 
thiazid-behandling var associeret med en øget ugentlig risiko for frakturer fra et i 
forvejen forøget risikoleje fra uge 0-42 i forhold til ikke-brugere, hvorefter der fra 
uge 43 observeredes en tiltagende lavere risiko for frakturer. Mellem 50- og 63-års 
alderen blev påbegyndelse af thiazid-diuretika fundet at have sammenlignelig 10-års 
risiko for frakturpådragelse sammenlignet med ikke-brugere, hvorimod 
påbegyndelse efter 63-års alder var associeret med en tiltagende øget risiko. At 
seponere behandlingen efter 73-års alderen var associeret med lavere 10-års risiko 
for frakturpådragelse sammenlignet med ikke-brugere. Lavere 
natriumkoncentrationer under indlæggelse var associeret med længere 
indlæggelsestider og højere samlede omkostninger, men med sammenlignelig 
genindlæggelsesrisiko. Hverken natriumkoncentrationer eller thiazidforbrug blev 
fundet at være stærke forudsigende faktorer for 5-års mortalitet eller 3-års udvikling 
af immobilitet hos ældre mænd.
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Prospektive studier er nødvendige for yderligere at belyse forholdet mellem 
hyponatriæmi og osteoporose, eksempelvis ved at måle biokemiske markører for 
knoglemetabolisme ved intervention fra hyponatriæmi til normonatriæmi. 
Herudover er flere kliniske studier af thiazid-vanddrivendes indflydelse på 
knoglemetabolisme og balance nødvendige for at skelne mellem hvem, der kan 
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1.1 - THIAZIDES, HYPONATREMIA AND OSTEOPOROSIS
The relationship between osteoporosis, thiazide diuretics and hyponatremia is one of 
intertwined effects that are both beneficial and harmful, often in paradoxical ways. 
All three matters are currently affecting Danish patients to a great extent. The 
Danish incidence of osteoporosis is increasing despite a large estimated prevalence 
of 500-600,000 people1. According to data available to our group, thiazide diuretics 
are among the ten most frequently prescribed pharmaceuticals in Denmark in the 
full 7-digit ATC system hierarchy2. Hyponatremia is a common electrolyte 
disturbance among hospitalized older patients, affecting almost 6-10% of older, 
hospitalized Danish patients3. 
While thiazide diuretics are known to cause hyponatremia4–7, known to be harmful 
to gait stability and postural balance8, retrospective studies have shown a protective 
effect of thiazides on fracture rates in both Europe and North America9–14. Similarly, 
recent studies have documented an association between hyponatremia itself and 
greater risks of osteoporosis15–20. For several decades, randomized clinical trials 
have investigated the direct effect of thiazides on bone mineral density21–25, but have  
not lead to a summarized conclusion about the role of thiazides in managing 
osteoporosis.
This thesis examines the effect of hyponatremia and thiazides on osteoporosis, 
fractures and similar fracture-related aspects, i.e. hospitalization burden and future 
mobility.
1.2 – OSTEOPOROSIS
1.2.1 - OSTEOPOROSIS AND FRACTURE RISK
Osteoporosis is defined by the WHO as “a systemic skeletal disease characterized 
by low bone density and microarchitectural deterioration of bone tissue with a 
consequent increase in bone fragility”26. 
In clinical practice, the disease is diagnosed either by the occurrence of a low-
energy fracture (hip or lumbar spine) or by BMD lower than certain thresholds. For 
the latter criteria, an estimation of BMD can be performed using DXA to define 
BMD in the lumbar spine and hip. This estimation of BMD in the femoral neck of 
the hip, the total hip and total lumbar spine region is then compared to peak bone 
mass of individuals of the same sex26. This can be used to assess the number of 
19
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standard deviations below or above peak bone mass and results in the statistical T-
score. The T-score and knowledge about concurrent fractures is then translated 
clinically to four categories (Table 1)27.
Table 1: WHO-defined categories of BMD28
Normal A value of BMD within 1 standard 
deviation of the young adult reference 
mean (T-score ≥ -1).
Low bone mass (osteopenia). A value of BMD more than 1 standard 
deviation below the young adult mean, 
but less than 2 standard deviations 
below this value (T-score < -1 and > -
2.5).
Osteoporosis. A value of BMD 2.5 standard 
deviations or more below the young 
adult mean (T-score < -2.5).
Severe osteoporosis (established 
osteoporosis).
A value of BMD 2.5 standard 
deviations or more below the young 
adult mean in the presence of one or 
more fragility fractures.
In a population of western women, the prevalence of osteoporosis increases with 
age, as the T-score is a component of age and BMD. At ages 50-59, 14.8% are 
expected to have osteoporosis, while the prevalence increases to 21.6% at ages 60-
69, 38.5% at 70-79 and 70.0% at ages above 80 years26. 
Osteoporosis can be defined as primary osteoporosis, i.e. age-related loss of bone 
mineral due to menopause in women or andropause in men, respectively, or 
secondary osteoporosis caused by comorbidities and/or medication that cause 
increased bone loss. This increased bone loss can be caused directly by recruiting 
and stimulating pro-resorptive osteoclasts, or by limiting anabolic osteoblast 
activities due to lower 25-hydroxycholecalciferol levels or osteoblast apoptosis1.  
Absolute decreases in T-score increase individual fracture rates exponentially 29, but 
the greatest proportion of affected individuals in the total population resides in the 
osteopenic group30. This can be explained by other risk factors for fracture, e.g. gait 
instability31, peripheral neuropathy32,33, poor postural balance34,35 and poor 
eyesight36. Fractures due to risk-prone behavior, e.g. specific types of physical 
activity, are also likely causes of this discrepancy. Fracture risk can be estimated by 
commercially available tools such as FRAX® which estimates 10-year risk of major 
osteoporotic fractures37. Among predictors of fractures, BMD explains the main part 
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of individual fracture risk, but prediction is further improved by adding knowledge 
of clinical risk factors38.
Osteoporosis is a widespread disease in Denmark, estimated to affect 500-600,000 
individuals1. In one older study, the lifetime risk of hip fractures in Western women 
was estimated to be 16%39. Hip fractures are associated with great burdens on the 
individual patient and on society in terms of hospitalization, convalescence and lost 
productivity40. Ageing populations in Western societies place a great need for 
identifying patients at risk of fractures by diagnosing osteoporosis, and alleviating 
factors that make individuals prone to falls. 
1.2.2 – BONE METABOLISM AND ELECTROLYTES
Bone tissue undergoes a continual process of resorption and anabolism to ensure an 
optimal balance between bone strength and elasticity. This process requires an 
intricate relationship between bone-resorbing cells, osteoclasts, and bone-forming 
cells, osteoblasts. The balance between resorption and anabolism changes 
throughout life due to age-related and hormonal effects41. BMD increases from birth 
until the age of 25-30 years, followed by a gradual decrease year by year with 
accelerated loss during the menopausal transition in women42. 
Human bone tissue is comprised of calcified tissue of organic matrix and calcium-
phosphate matrix tissue, hydroxyapatite43, that ensure both mechanical strength and 
elasticity to withstand the effects of gravity. Pro-resorptive factors increase the size 
and activity of osteoclasts which adhere to the trabecular surface and resorb bone 
through acidic protease release. The resulting bone resorption recruits bone-forming 
pre-osteoblasts to the bone tissue site. Osteoblasts form osteoid out of collagen and 
proteins44, which mineralizes to calcified tissue. Osteoblasts regulate osteoclast 
resorption through stimulation by nuclear factors (i.e. RANK ligand45) and 
inhibition through the decoy OPG46, which inhibits RANK ligand. This relative 
activity between osteoblasts and osteoclasts is highly dependent on hormonal 
aspects, particularly age-related aspects. As such, progressively increased anabolism 
continues until age 25-30 years where peak bone mass is attained47, following by 
progressively increased resorption that further accelerates during the menopausal 
transition due to estrogen depletion48,49.
Several specific hormonal agents are involved in bone metabolism, but especially 
the effects of vitamin D (25-hydroxycholecalciferol and 1,25-
dihydroxycholecalciferol), PTH and FGF-23 are important for post-menopausal 
osteoporosis and calcium metabolism50,51. In the event of low or high extracellular 
calcium, the CaSRs of the parathyroid glands undergo conformational changes to 
secrete or cease secretion of PTH from the parathyroid glads52. In the kidneys, the 
CaSR exerts several effects across the nephron, i.e. sodium secretion in 
hypercalcemia in thick ascending limb and distal tubule. 53. In hypocalcemia 
specifically, this facilitates an increase in serum calcium due to increased bone 
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resorption, and also decreases serum phosphate due to increased renal secretion. 
Further, the increase in PTH accelerates conversion of 25-hydroxycholecalciferol to 
active 1,25-dihydroxycholecalciferol, which induces RANK-ligand production41 in 
osteoblastic cells and thereby promotes osteoclastic bone remodeling to mobilize 
calcium from the skeleton. 1,25-dihydroxycholecalciferol also increases 
gastrointestinal absorption of calcium and phosphate54. However, the 
pharmacological form of 1,25-dihydroxycholecalciferol, calcitriol, improves BMD 
in post-menopausal osteoporosis55. PTH directly and indirectly alters renal excretion 
of most electrolytes. For calcium and phosphate specifically, the hormone increases 
renal excretion56. FGF-23 is produced in response to increased 1,25-
dihydroxycholecalciferol and hyperphosphatemia. The growth factor increases renal 
excretion of phosphate and inactivates 1,25-dihydroxycholecalciferol57.
1.3 – HYPONATREMIA
Hyponatremia is defined as low serum concentrations of sodium. Depending on 
geography and assay specification, reference values of serum sodium range between 
135-145 mmol/L or 137-147 mmol/L58,59.
Regulation of serum sodium is dependent both on renal reabsorption of sodium 
regulated by RAAS60–62 and renal water retention by vasopressin and aquaporins63–
66. Of total body water, approximately 60% resides as intracellular (ICF) and 40% as 
extracellular fluid (ECF). Water flows between the ICF and ECF to maintain 
osmolality which is comprised of ions, e.g. sodium, potassium, calcium, magnesium 
and phosphate, and ineffective substances, e.g. glucose and urea. Sodium is the 
predominant extracellular ion alongside the anion chloride.
Table 2: Formulas for calculated plasma osmolality
P-Osmolality = 2 x [Sodium] + 2 x [Potassium] + [Glucose] + [Urea]
or
P-Osmolality = 2 x [Sodium] + [Glucose] + [Urea] 67,68
1.3.1 - SERUM SODIUM IN RESPONSE TO HYPOVOLEMIA
Sodium forms a critical part of vascular volume. In the event of hypovolemia in the 
intravascular compartment, jugular baroreceptor and renal juxtaglomerular 
responses stimulate juxtaglomerular cells to increase conversion of pro-renin to 
renin. When released into circulation, renin converts angiotensinogen to 
angiotensin-I, which is then converted to angiotensin-2 by ACE69,70. The resulting 
increase in angiotensin-2 both increases arterial blood pressure through 
vasoconstriction and promotes production of aldosterone in the adrenal glands71,72. 
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Aldosterone increases renal reabsorption of sodium through three primary 
mechanisms; 1) increased activity of the basolateral Na+/K+-ATPase of the distal 
tubule and collecting ducts of the nephron73, 2) by increasing activity of the ENaC 
channels of the renal collecting ducts74,75, and 3) by increasing NCC activity in the 
distal tubule76. The resulting increase in intravascular sodium content, coupled with 
increased water retention, increases intravascular volume and lowers baroreceptor 
response progressively as euvolemia is attained. The increased angiotensin activity 
augments the effect of AQP in the renal collecting ducts77.
1.3.2 - SERUM SODIUM IN RESPONSE TO INCREASED PLASMA 
OSMOLALITY
The major component of body water regulation is the water-electrolyte balance 
inherent in plasma osmolality. With greater loss of free water, i.e. by perspiration, 
renal or gastroenterological excretion, the serum concentration of sodium increases 
with an even greater increase in plasma osmolality, per the formula of osmolality 
listed above78–81. At plasma osmolalities above 275-295 mosm/kg, hypothalamic 
osmoreceptors are activated to increase hypothalamic production of vasopressin 
preprohormone, followed by increased pituitary release of vasopressin82,83. The 
relation between osmolality and vasopressin production is exponential from an 
individual set-point of increased production. Vasopressin acts on the renal collecting 
ducts by increasing AQP (mainly AQP-284) insertion in the apical membrane85,86 to 
facilitate free-water retention from the dilute urine made available in this portion of 
the nephron87. The resulting dilution of serum by free water results in progressively 
lower plasma osmolality towards the normal reference, whereby the vasopressin 
response decreases.
1.3.3 - HYPONATREMIA AS A DISORDER OF SERUM SODIUM 
REGULATION
Hyponatremia has traditionally been categorized by two categories; 1) acute versus 
chronic hyponatremia, and 2) hypovolemic, euvolemic, and hypervolemic 
hyponatremia88–90. 
1.3.3.1 – ACUTE VERSUS CHRONIC HYPONATREMIA
The differentiation between acute hyponatremia and chronic hyponatremia relates 
to the urgency of which the condition has emerged, and has substantial effects on 
the bodily ability to adapt to changes in osmolality. 
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With acute hyponatremia, commonly defined as occurring within a 48-hour onset 
(e.g. by acute polydipsia), the rapid decrease in serum osmolality results in sudden, 
large shifts in free-water between the vascular and cerebral space, leading to brain 
edema, increased ICP and a clinical spectrum from somnolence to seizures, coma 
and respiratory arrest. This condition warrants a prompt elevation of serum sodium 
typically through hypertonic saline91,92. 
In chronic hyponatremia, less-rapid decreases in serum sodium allow the cerebral 
space to adapt to chronically lower plasma osmolality, resulting in decreased 
cerebral volume. This condition has been referred to as “asymptomatic 
hyponatremia”93, but is increasingly recognized to affect cognitive performance8,94, 
gait stability and physical performance negatively94. Due to the chronic adaptations 
of the cerebral space, the therapeutic approach to chronic hyponatremia is not one of 
rapid correction as in acute hyponatremia, but of slowly increasing serum sodium, 
i.e. by discontinuing causal pharmaceuticals, treating comorbidities or restoring 
sodium content through isotonic saline95. Suggestions of how quickly to raise serum 
sodium vary in European and North American treatment guidelines. Raising serum 
sodium too abruptly in chronic hyponatremia runs a substantial risk of osmotic 
demyelination syndrome with permanent neurological disability96.
1.3.3.2 – HYPOVOLEMIC, EUVOLEMIC AND HYPERVOLEMIC 
HYPONATREMIA
A further traditional segmentation of hyponatremia has involved the presence of 
concurrent hypovolemia, euvolemia or hypervolemia. The volume state relates to 
the relative loss, maintenance or abundance of free-water and sodium in the 
extracellular space89. 
In hypovolemic hyponatremia, loss of free-water with greater simultaneous loss of 
sodium results in decreased intravascular volume and hyponatremia. This condition 
can be caused by gastroenterological expulsion (e.g. gastroenteritis, chronic 
inflammatory bowel disease, malignancy-related vomiting), skin burns, diuretics use 
(e.g. furosemide, thiazides and potassium-sparing diuretics) and cortico- or 
mineralocorticoid deficiency (e.g. Addison’s disease).88 This condition is 
therapeutically managed by discontinuing aggravating pharmaceutical agents, 
replenishing extracellular volume through saline and/or treating any underlying 
pathological condition90.
In euvolemic hyponatremia, increased free-water in the presence of normal, 
physiologic sodium content in the ICF dilutes serum sodium with no effect on 
volume status. This can be caused by increased oral water intake (e.g. 
polydipsia97,98) or renal retention of water inappropriate to plasma osmolality. The 
latter condition has historically been referred to as the Schwartz-Bartter syndrome99, 
24
24
but has in recent decades been rephrased as SIADH, per the original author’s 
reference. This condition involves plasma levels of vasopressin that are elevated 
inappropriately to current plasma osmolality, e.g. high vasopressin concentrations at 
plasma osmolalities where vasopressin production is normally suppressed to 
immeasurable levels (for instance, 260 mmol/L). Increased vasopressin levels at 
these osmolalities allow for water retention and thereby dilution of serum sodium. 
SIADH can be caused by pharmaceutical agents (e.g. selective serotonin reuptake 
inhibitors100–102 or antiepileptics103) and/or pathological conditions (e.g. 
malignancy104105, nausea106, inflammation and acute infections107). Therapeutic 
management involves restrictions of oral water intake108, discontinuation or 
replacement of aggravating agents (e.g. selective serotonin reuptake inhibitors to 
serotonin–norepinephrine reuptake inhibitor), curing causal conditions (e.g. tumor 
extirpation109) or by competitively inhibiting vasopressin actions (i.e. vasopressin 
antagonists; vaptans110).
In hypervolemic hypernatremia, increased sodium retention with even greater water 
retention results in expanded extracellular volume with concurrent hyponatremia 
due to dilution111. In conditions of reduced effective vascular volume, i.e. chronic 
renal injury112, congestive heart failure and hepatic cirrhosis113, inappropriately 
active baroreceptor and juxtaglomerular responses increase RAAS activity and 
facilitate increased renal sodium retention. The resulting increase in plasma 
osmolality increases hypothalamic stimulation of pituitary vasopressin release and 
thereby increases renal water retention, but the mechanism itself has also been 
shown to augment the relative effect of vasopressin of aquaporin synthesis in the 
renal collecting ducts. Clinical edema is commonly observed in hypervolemic 
hyponatremia88. In a similar condition of increased sodium retention by increased 
aldosterone production, Conn’s syndrome, effective vascular volume is not reduced 
and atrial natriuretic peptides prevents formation of edema114. Therapeutic 
management of hypervolemic hyponatremia involves managing the underlying 
condition pharmaceutically (i.e. ACE inhibitors, beta-receptor antagonists, 
spironolactone, diuretics), by assisting devices (i.e. pacemaker therapy, dialysis), by 
surgery (i.e. transplantation) and/or by a symptomatic approach (i.e. water 
restriction, diuretics)115.
1.4 – HYPONATREMIA AND OSTEOPOROSIS
In several population studies, a possible relationship between hyponatremia and 
osteoporosis has been investigated during the past decade. A large North American 
study revealed an association across all age-groups between lower serum sodium 
and higher risk of osteoporosis116. In Europe, a Danish study showed a significant 
relationship between lower serum sodium and lower total hip BMD, but no 
significant association to lumbar spine BMD16. A smaller South Korean study 
showed an association between osteoporosis and hyponatremia17. In specific patient 
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groups, patients with anorexia nervosa between ages 17 and 54 showed lower BMD 
values with decreases in serum sodium in a cross-sectional study117,118. Some studies 
have also shown a more neutral association between serum sodium and BMD119, 
while there are no studies showing evidence of a protective association between 
hyponatremia and osteoporosis. In a systematic review and meta-analysis by Upala 
et al.120, some of the mentioned papers were combined and showed a relationship 
between hyponatremia and higher risks of both osteoporosis and fractures.
In a rat model study of the possible cellular explanations for this relationship, 
Verbalis et al. compared the effect on bone metabolism of chronic hyponatremia 
induced by free water infusion versus normonatremia maintained by a solid diet. 
Both rat models received injections of 25-hydroxycholecalciferol. After three 
months, the hyponatremic rat model showed greater loss of cortical and trabecular 
bone volume and worse trabecular number, indicating that hyponatremia can induce 
BMD loss and structural bone deterioration121. From the same group, a further 
cellular study by Barsony et al.20 induced different severities of hyponatremia to 
colonies of bone stem cells and adjusted for the resulting lower osmolality through 
insoluble mannitol. Murine macrophages increased in both size and resorptive 
capability when exposed to hyponatremia, following a dose-response association 
with greater resorptive ability and greater resorption of dentin with lower 
concentrations of sodium. Fibbi et al.122 has examined mesenchymal stromal cells, 
the precursor to bone-forming osteoblasts, and found an inclination towards 
adipocyte differentiation instead of osteoblasts in an environment of hyponatremia. 
This has the potential to hamper bone formation in humans. 
Separate cellular studies of vasopressin knock-out in relation to bone resorption and 
bone anabolism has implicated a causal relationship between increased vasopressin 
and changes in cellular metabolism, favoring resorption by activating 
osteoclasts123,124. Other studies, among them an in vitro study by Sun et al.124, 
showed no relation between vasopressin and bone resorption, but stressed that the 
relationship is intricate to other pituitary hormones, i.e. oxytocin. Increased 
proliferation of osteoblast-like cell has been shown by Lagumdzija et al.125. 
Conversely, the condition of absent vasopressin production, diabetes insipidus, has 
also been associated with detrimental bone loss126.
1.5 – HYPONATREMIA, FALLS AND FRACTURE RISK
Several retrospective population studies have shown evidence that hyponatremia 
affects fracture risk negatively, i.e. non-vertebral fracture risk in The Netherlands119, 
overall fracture risk in Ireland127 and Belgium128 and both hip and overall fracture 
risk in North American studies129,130. Specifically for falls, regardless of fracture 




A plausible explanation for the increased fracture risk was published by Renneboog 
et al., who showed gait stability and postural balance to be negatively affected by 
hyponatremia, but reversible with normalization of serum sodium8. Further 
neurological and cognitive deterioration94,132 symptoms and hypotension-prone 
reactions to hyponatremia have also been speculated to affect fall and fracture risk. 
In an older dose-response study by Arieff et al.133, a correlation was found between 
lower serum sodium models in humans and rabbits with greater severity of certain 
neurological symptoms, i.e. somnolence and seizure incidence. A further 
symptomatology study has been performed by Chow et al.134. Through chart 
reviews, hyponatremia was shown to be commonly related to dizzy spells and to 
vasovagal symptoms, e.g. vomiting, which could temporary lower systolic blood 
pressure and cause fainting episodes.
1.6 – THIAZIDES
Thiazide diuretics (ATC codes C03AB and C03AA) form a group of pharmaceuticals 
used to treat hypertension and disturbances of calcium excretion. The first 
commercially available thiazide, chlorothiazide, was introduced in 1958 and has 
since been widely used to increase renal excretion of sodium not only in 
hypertension, but also cirrhosis, congestive heart failure and chronic renal failure 
with edema135–137. Thiazides act on the distal tubule of the nephron by inhibiting 
sodium reabsorption in the NCC138–140. This results in several antihypertensive 
mechanisms whose relative importance is not fully understood; decreased renal 
reabsorption of sodium causes increases diuresis141–143, lower extracellular volume 
decreases cardiac output144–146 and, speculatively, lowers peripheral vascular 
resistance over time. 
In Denmark, thiazide diuretics are a widely used antihypertensive agent and is 
recommended by the Danish Hypertension Society as on the four primary choices 
for older patients with no competing comorbidity that warrant newer agents, e.g. 
ACE-inhibitors and ARBs147. In registry data of 3.1 million Danes used for the 
papers of this thesis, thiazide diuretics are among the top ten most widely used 
agents of all the 7-digit ATC agents2. While this widespread use indicates that 
thiazides are a well-tolerated agent in the general population, side-effects have been 
documented both as subjective symptoms and as asymptomatic alterations of 
electrolyte metabolism. Hyponatremia, hypercalcemia and hypomagnesemia are 
known to occur in 0.1-1% of users, while hypokalemia and hyperglycemia are 
known to occur for more than 10% of users (Appendix 8).
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1.6.1 – THIAZIDES AND HYPONATREMIA
For a subset of patients, this intended renal excretion of sodium caused by thiazide 
diuretics can reach inappropriate proportions and stimulate other physiological 
mechanisms that lower plasma sodium levels disproportionally. The phenomenon of 
thiazide-induced hyponatremia has been known since the introduction of the 
pharmaceutical148 and was feared for its possible neurological complications134,149–
151. Thiazide-induced hyponatremia is thought to occur due to inappropriate 
responses to the pharmaceutical and its effect on water and osmolality physiology. 
Increased renal excretion of sodium lowers intravascular volume and sodium 
content152–155, which inappropriately increases vasopressin production and augments 
the effect of ADH on AQP-receptors in the distal portions of the nephron. This 
results in increased subjective sensations of thirst and increased oral hypotonic 
water intake148,156,157 in thiazide users, diluting plasma sodium. More than 10% of 
Danish thiazide users are estimated to develop hyponatremia after commencing 
thiazide therapy (Appendix 8). The absolute decrease in plasma sodium is however 
unpredictable and relates to concurrent medication use158,159, i.e. SSRIs and other 
natriuretic agents. Comorbidities affecting water metabolism, i.e. SIADH-prone 
malignancy, chronic inflammation and edema-related conditions also figure with 
unknown weights, as do anthropometrics, i.e. low body weight and higher age160–162.
1.6.2 - THIAZIDES AND OTHER ELECTROLYTE DISTURBANCES
Thiazide diuretics similarly alter renal excretion of other electrolytes, i.e. calcium, 
potassium and magnesium. 
Increased renal reabsorption of calcium is known to occur with thiazide use relative 
to the increases in renal excretion of sodium. This can lead to clinical 
hypercalcemia163–165. Thiazide-induced inhibition of the NCC decreases luminal 
availability of sodium which facilitates increased activity in the NCX1166,167. This 
increases reabsorption of calcium from the urine side via the calcium-selective 
TRPV5 protein168,169. This effect has been documented to occur within 14 days of 
commencing thiazide diuretics170. The effect was originally considered to increase 
parathyroid activity in canine models171, but has in later randomized controlled trials 
been shown to maintain PTH levels172, as hypomagnesaemia can also occur with 
thiazide use173. In patients with PHPT, serum calcium levels can further increase 
with thiazide use, although this is related to hypochloremia-related alkalosis pseudo-
increases in albumin-adjusted serum calcium174.
Hypokalemia is known to occur in more than 10% of thiazide users, particularly if 
the pharmaceutical is administered without potassium chloride supplementation175. 
The proposed mechanism relates to NCC inhibition of sodium reabsorption in the 
distal tubule, which increases availability of sodium in the collecting ducts. 
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Increased availability of sodium facilitates reabsorption through the Na+/K+-ATPase 
and increases renal excretion of potassium176–179. Thiazide-induced hypokalemia is 
related to metabolic alkalosis and arrhythmias ranging from premature ventricular 
contractions to ventricular fibrillation180. 
Hypomagnesemia is known to occur in 0.1-1% of Danish thiazide users (Appendix 
8). Similar to hypokalemia, the condition is caused by altered availability of sodium 
at the cellular level of the distal convoluted tubule which increases renal 
reabsorption of calcium. This downregulates activity of the TRPM6 transporter and 
facilitates magnesium reabsorption to the luminal side181. The phenomenon is 
similar to inherited diseases of hypomagnesaemia, i.e. Gittelman’s disease182–184.
1.6.3 – THIAZIDES AND BMD
The effect of thiazides on osteoporosis and disorders of calcium metabolism has 
been studied for several decades, both retrospectively and through prospective 
clinical trials. 
A randomized, clinical trial spanning four years was conducted by the Reid and 
Bolland group185,186 between 2000 and 2007 and documented small, positive effects 
on total body, mid- and distal forearm BMD. A randomized controlled trial of 
alendronate versus alendronate and thiazides by Arrabol-Polo et al.187 in 2013 
showed improved total hip, femoral neck and lumbar spine BMD with added 
thiazide use. In 2000, LaCroix et al. documented a protective effect on hip and 
lumbar spine BMD with thiazide use compared to placebo23.
A large retrospective, cross-sectional study by Wasnich et al. in 1983 discovered an 
association between thiazide use and increased BMD in distal portions of the upper 
and lower extremities188. A neutral effect of thiazide on hip and radial BMD was 
documented by Ooms et al. in a retrospective cross-sectional study in 1993189. 
Cauley et al. documented a positive association between thiazide use and distal 
radius BMD in 1993190. A detrimental 5-year effect on radial bone by thiazide use 
was documented by Sowers et al. in a cohort study in 1993191. Sigurdsson reported a 
positive effect of thiazide use on lumbar spine BMD in women in a cross-sectional 
study in 2001192.
On the cellular level of bone, thiazides have been shown to increase osteopontin and 
runx2 levels as an indicator of stimulated osteoblast differentiation. A possible 




1.6.4 – THIAZIDES, FALLS AND FRACTURE RISK
Several large, retrospective epidemiological studies have examined the role of 
thiazides and thiazide-induced hyponatremia in fracture and fall risk. Prospective 
research has also been performed on the effect of thiazides on gait instability and 
postural balance. 
In cross-sectional population-based studies, thiazides have been associated with 
greater risks of falls in older people194–197, while some studies have shown the 
association to be neutral190,198. A probable explanation for the increased incidence of 
falls is poor postural balance and gait instability associated with hyponatremia, a 
condition often caused by thiazide use8. By correcting hyponatremia, it has been 
shown that gait stability can be improved and thereby limit the risk of falls8.
Conversely, when examining thiazide use and fracture risk regardless of falls, 
thiazides have been shown to be protective against fractures in European and North 
American studies. This has been documented in prospective cohort studies199,200, 
retrospective cohort studies201 and case-control studies202,203. A duration-response 
effect has been shown in some studies204,205 and rejected in others11. Berry et al. 
documented an increased fracture risk shortly after the onset of thiazide therapy 
which then subsided with continued use206. Specific studies have shown mixed 
effect sizes, i.e. protection from hip and wrist fractures, but neutral risk towards 
other osteoporotic fractures190. Neutral effects have also been documented14,207. One 
specific study by Chow et al.208 of patients with thiazide-induced hyponatremia did 
not show a significant association with fracture risk. A harmful effect has also been 
published in one case-control study209.
1.7 – SUMMARY
Several large, population-based studies across various territories have shown a 
protective effect of thiazide use on fracture risk, with some studies also showing 
further improvement with longer duration and higher treatment doses. This can be 
explained pharmacologically by thiazide-induced increases in renal calcium 
reabsorption which provides components for mineralization and improves bone 
formation directly on the cellular level of osteoblasts. Several randomized controlled 
trials of thiazides and BMD have been performed and shown causal improvements 
at specific regions of interest, but no universal effect that has warranted 
recommendation in clinical practice.
Hyponatremia is a condition of diluted serum sodium due to several solitary or 
combined pharmaceuticals and diseases. Primarily in large retrospective studies, but 
also prospectively, this condition has in itself been associated with increased falls 
and fracture risk, likely due to poor gait stability, physical performance and postural 
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balance. On a cellular and epidemiological level, hyponatremia has been associated 
with greater bone resorption, lower BMD and a higher risk of osteoporosis. With 
and without osteoporosis, hyponatremia has been shown to increase the risk of falls 
and fractures due to the aforementioned symptomatology. Thiazides have been 
shown to causally induce hyponatremia in a subgroup of patients.
Absent from this intertwined positive and negative relationship between thiazides, 
hyponatremia and osteoporosis is a clear and stratified treatment strategy. No 
summarized conclusion has been made as to which patient groups should be 
prescribed the agent to improve BMD and protect from fractures, and who should 
refrain from commencing therapy due to risks of hyponatremia and the increased 
fracture risk associated herewith. 
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2. AIM AND HYPOTHESES
2.1 - PRIMARY HYPOTHESES
1. Hyponatremia is associated with lower BMC and BMD, and a higher risk 
of osteoporosis compared to normonatremia.
2. Thiazide use is protective against fracture occurrence in certain female age 
groups.
2.2 - SECONDARY HYPOTHESES
1. Chronic hyponatremia is associated with worse progression of osteoporosis 
compared to chronic normonatremia.
2. Thiazide use improves BMD compared to none-use.
3. Long-term thiazide use is necessary to obtain a protective effect against 
fracture occurrence.
4. Thiazide use alters urinary excretion of electrolytes in a matter that is 
beneficial to osteoporosis.
5. Hyponatremia is associated with greater comorbidity and economic 
burdens among hospitalized patients.
6. Hyponatremia is predictive of mortality.
2.3 - AIMS OF THIS THESIS
1. To examine an association between hyponatremia, bone mineral density 
and osteoporosis in a population-based sample.
2. To examine the effect of chronic hyponatremia on osteoporosis 
progression.
3. To examine the relative risk of fractures in thiazide users versus non-users 
based on age of commencing therapy.
4. To investigate the effect of long-term thiazide use on fracture risk.
5. To examine the combined evidence of a beneficial role of thiazides on bone 
mineral density from existing clinical trials.
6. To rank the relative importance of hyponatremia in mortality and incident 
immobility among older men.
7. To investigate the effects of hyponatremia on hospitalization length of stay 
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3.1 - PAPER 1
3.1.1 MATERIALS AND METHODS
3.1.1.1 - DESIGN
This work was a retrospective cross-sectional study examining the relationship 
between serum sodium and DXA-based BMD values in Danish outpatients. Data 
available from 2004 to 2011 were linked to national Danish patient registries to 
investigate a potential association and potential causes of hyponatremia to further 
investigate.
3.1.1.2 - REGISTRIES AND EXPOSURE VARIABLES
3.1.1.2.1 -  REGIONAL DXA SCAN DATABASE
The DXA scan database consisted of data from one regional center conducting DXA 
scans on referred outpatients; the Department of Endocrinology at Aalborg 
University Hospital, Denmark. DXA scan data were available from 2004 to 2011. 
The database included two separate tables of hip and lumbar spine DXA scans and 
the underlying anthropometry data of scanned patients (i.e. height in centimeters and 
weight in kilograms). Scanned regions of interest at the hip were femoral neck, 
trochanteric, intertrochanteric, Ward’s triangle and total hip. Scanned regions of 
interest at the lumbar spine were L1-L4 and the total lumbar spine. Collected 
variables were BMC, bone area and BMD for these regions. For the total hip, 
femoral neck and total lumbar spine, BMD was used to calculate T-score based on 
sex, age and ethnicity. All the DXA scan data had been collected using Hologic™ 
machines (Hologic 1000, Hologic 2000, Hologic Discovery). All machines 
underwent a QC program of phantom scans and cross-calibration to limit drift over 
time. LSC was below 3% for lumbar spine and total hip measurements and below 
5% for femoral neck measurements.
3.1.1.2.2 - REGIONAL BIOCHEMICAL SAMPLES DATABASES
From the same center, data on all biochemical samples drawn from the 
aforementioned scanned patients were added to this work. The data collection 
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period spanned 1996 to 2012 and was collected from the Department of 
Biochemistry at Aalborg University Hospital. Both were certified by national 
agencies (i.e. DANAK, Appendix 9) with publicly available information of 
precision error. The data consisted of date and time of sampling, analysis label (i.e. 
NPU code), numerical value and reference intervals. The data were structured in a 
long format for relational purposes.
3.1.1.2.3 - NATIONAL DANISH PATIENT REGISTRIES
Data on prior prescription reimbursement and existing patient diagnoses were 
collected from the National Danish Patient Registry. 
Prescription information included date of reimbursement, ATC code up to a 7-digit 
level, numerical and DDD doses, price of reimbursement, package size and number 
of packages. Patient diagnoses information consisted of date of diagnosis, ICD-10 
code up to decimal sub-description and whether the diagnosis was made in an in- or 
outpatient setting. 
3.1.1.3 - THE STUDIED POPULATION
The DXA scan tables of hip and lumbar spine data were examined separately. The 
scans were linked by CPR identification number to biochemical data via this 
identifier. Serum sodium values drawn closest to each scan date, if drawn within 14 
days before or after the scan date, were selected. From the resulting serum sodium 
values, values at or below 145 mmol/L were included for further studied. A further 
categorization of “hyponatremia” as [Na+] < 135 mmol/L and “normonatremia” as 
[Na+] = [135-145] mmol/L was done. Non-numeric and incomplete DXA scans 
were excluded. Subjects younger than 25 years of age, a weight below 30 kg or a 
height below 130 cm were excluded. BMI was calculated from these weights and 
heights. Cases without complete data on weight and height were excluded. Based on 
the scan dates, total numerical consumptions in DDD of selected pharmaceuticals 
within the prior 5 years were calculated. BMD values were used to establish T-
scores and WHO-defined bone status, i.e. normal BMD, osteopenia or osteoporosis. 
Further categorizations of “Osteoporosis without hyponatremia” and “Osteoporosis 
with hyponatremia” were performed.
3.1.2 - STATISTICAL ANALYSIS
Descriptive statistics included mean, SD and range for numerical variables. 
Between-group comparisons were performed by independent samples T-tests. 
Comparisons were made between “Hyponatremia” and “Normonatremia”, and 
between “Osteoporosis with hyponatremia” versus “Osteoporosis without 
hyponatremia”. For categorical data, odds-ratios were calculated and statistical 
comparisons performed between groups performed through Chi-square (χ2) 
analysis. Logistic regression was performed to establish dose-response risk of 
numerical serum sodium and risk of osteoporosis. Crude odds ratios were 
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established, followed by odds ratio calculations adjusted for age, gender and BMI. 
Multiple linear regressions were performed between serum sodium levels below 135 
mmol/L and BMD, BMD and T-scores in all regions of interest, both crude slopes 
and slopes adjusted for age, gender and BMI.
3.1.3 - SUMMARY OF RESULTS
1,575 patients met the inclusion criteria. Of these, 104 (6.6%) had hyponatremia 
while 1,462 (93.4%) were normonatremic (Table 3). Patients with hyponatremia 
were significantly older (mean age 68.77 ± 10.07 vs 62.71±13.78 years, p < .05), 
presented with lower weight (67.15 ±16.61 vs 72.31 ±16.29 kg, p < .05), height 
(1.62 ± .09 vs 1.65 ± .09 meters, p < .05) and BMI (25.48 ± 5.12 vs 26.52 ± 5.21, p 
< .05), and ran higher risks of existing lumbar fractures (3.8% vs. 1.2%, p < .05) 
(Table 3). Hyponatremic patients had significantly higher use of benzodiazepines, 
beta-receptor antagonists and opioids and were more likely to have existing 
diagnoses of gynecological and urological malignancy (OR 3.40 and 4.80 
respectively, p < .05), epilepsy (OR 4.79, p <  .05), sero-positive rheumatoid 
arthritis (OR 3.25, p < .05) and ischemic heart disease (1.76, p < .05). Numerical 
increases in serum sodium below 145 mmol/L were associated with a lower risk of 
categorical osteoporosis at either the lumbar spine or hip. This association persisted 
after adjustment at either the hip or lumbar spine (OR .951 [.916-.986], p < .05) and 
the hip regardless of lumbar spine BMD (OR .948 [.910-.989], p < .05), but not in 
the lumbar spine alone regardless of hip BMD (OR 0.979 [.943-1.017], p = .277) 
(Table 4). A linear relation was established between serum sodium below 135 
mmol/L and both BMC, BMD and T-scores in all regions of the hip, but not of the 
lumbar spine. This relationship persisted after adjustment (Table 5).
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Age at scan 62.71 (13.78) (69.00) 68.77 (10.07) 
(51.00)
.000 *
BMI 26.52 (5.21) (39.30) 25.48 (5.12) 
(32.15)
.049 *







Height 1.65 (.09) (.62) 1.62 (.09) (.48) .001 *







1129 (77.2 %) 81 (77.9 %) .876
Prior lumbar 
spine fracture
18 (1.2 %) 4 (3.8 %) .038 *
Prior hip 
fracture










0.93 (.18) (1.15) 
(1024)
0.88 (.19) (.99) (81) .036 *
Spine, T-score −1.24 (1.58) (10.44) 
(1462)





3.69 (.84) (5.27) 
(1462)





0.69 (.14) (1.08) 
(1462)










0.82 (.16) (1.16) 
(1462)





−1.39 (1.28) (9.66) 
(1462)
-1.91 (1.25) (6.85) 
(104)
.000 *
*: p < .05
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Table 4: Total OR for osteoporosis
Condition OR 95% CI Significant 
p-value
Total OR for osteoporosis, either total hip or 
lumbar spine
- Increasing plasma concentration Na+ 
(for [Na+] <145 mmol/L) adjusted 




Total OR for osteoporosis, total hip region 
regardless of lumbar spine
- Increasing plasma concentration Na+ 
(for [Na+] <145 mmol/L) adjusted 




Total OR for osteoporosis, lumbar spine 
regardless of total hip
- Increasing plasma concentration Na+ 
(for [Na+] <145 mmol/L) adjusted 




*: p < .05
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Table 5: Multiple regression, the relationship between [Na+], BMC, BMD, and T-
scores for [Na+] <135 mmol/L








Spine, L1 BMC .038 .028 .168 .187
Spine, L1 BMD .002 .001 .215 .522
Spine, L2 BMC .053 .031 .085 .108
Spine, L2 BMD .002 .002 .156 .448
Spine, L3 BMC .068 .034 .044 * .061
Spine, L3 BMD .002 .002 .354 .744
Spine, L4 BMC .068 .038 .075 .090
Spine, L4 BMD .002 .002 .242 .470
Spine, total BMC .228 .123 .063 .076
Spine, total BMD .001 .002 .472 .717
Spine, T-score .009 .013 .464 .998
Hip, trochanter BMC .050 .018 .005 * .001 *
Hip, trochanter 
BMD








.004 .002 .005 * .037 *
Hip, neck BMC .020 .007 .003 * .005 *
Hip, neck BMD .003 .001 .005 * .041 *
Hip, Ward’s BMC .005 .002 .002 * .020 *
Hip, Ward’s BMD .004 .001 .001 * .015 *
Hip, total BMC .174 .069 .012 * .003 *
Hip, total BMD .004 .001 .002 * .012 *
Hip, T-score .034 .010 .001 * .012 *
*: p < .05
40
40
3.2 - PAPER 2
3.2.1 - MATERIALS AND METHODS
3.2.1.1 - DESIGN
This study was a retrospective cohort work examining the relationship between 
persistent hyponatremia and its temporal effects on DXA-based BMD values in 
Danish outpatients. Data available from 2004 to 2011 were linked to national 
Danish patient registries to perform the study.
3.2.1.2 - REGISTRIES AND EXPOSURE VARIABLES
3.2.1.2.1 - REGIONAL DXA SCAN AND BIOCHEMICAL SAMPLES 
DATABASE
The DXA scan databases consisted of all data from two regional centers conducting 
DXA scans on outpatients; the Departments of Endocrinology at Aalborg and 
Aarhus University Hospital, both in Denmark between 2004 and 2011. The 
biochemical samples database was extracted from the Departments of Biochemistry 
at Aalborg University Hospital and Departments of Biochemistry and Microbiology 
at Aarhus University Hospitals, both DANAK certified institution (Appendices 9 
and 11), based on the list of scanned patients.
3.2.1.2.2 - NATIONAL DANISH PATIENT REGISTRIES
Data on prior prescription reimbursement and existing patient diagnoses were 
collected from the National Danish Patient Registries.
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3.2.1.3 - THE STUDIED POPULATION
Patients were included among all DXA scanned patients of both sexes who were 
older than 25 years of age, above 120 cm tall, weighted more than 30 kg and had 
undergone more than one lumbar spine or hip scan. The procedures were then done 
separately for hip and lumbar spine scan tables. The first and last hip and lumbar 
spine DXA scans for each patient were selected. Patients were excluded if less than 
24 months had gone between the first and last scans. Patients with known diabetes 
mellitus were excluded based on existing diagnoses, HbA1c measurements above 48 
mmol/mol or antidiabetics use. Patients without at least one sodium measurement in 
40% of observed quarters between the dates were excluded. For all DXA scanned 
regions of interest, absolute and annualized changes in BMC and BMD were 
calculated. Absolute and annualized changes in height, weight and BMI were also 
calculated. Between the dates of the first and last scan, all blood samples of sodium 
were pooled, and from them, mean and 95% CI of the mean calculated. From the 
CIs, patients were categorized as having either “normonatremia”, defined as a 
sodium level of [137.00;147.00] mmol/L or “mild hyponatremia” as a sodium level 
of [130.00;137.00] mmol/L. For all subjects, categorical presence of co-existing 
diagnoses between January 1st, 1996 and the scan date was established. CCI scores 
were calculated for each individual at the scan date. Prescription reimbursements for 
specific pharmaceuticals were calculated from January 1st, 1996 to the date of the 
first scan, and from between the first to the last scan. Changes in BMC, BMD in all 
regions of interest were calculated for each group both as crude changes and change 
adjusted for age, sex, length of observation, prior hip and lumbar spine fractures and 
exposure to glucocorticoid (ATC code H02AB), bisphosphonate (ATC code 
M05BA) and drugs used in alcohol dependence (ATC code N07BB) from ATC 
codes.
3.2.2 - STATISTICAL ANALYSIS
Descriptive statistics included mean, SD and range for numerical variables. For 
categorical data, odds ratios were calculated and statistical comparisons performed 
between groups through Chi-square (χ2) analysis. 95% CI was calculated from a t-
distribution of +/-1.96. Independent samples t-tests were performed between 
“normonatremia” and “mild hyponatremia”. Multiple regression was used to adjust 
for age, sex, length of observation, medication use and existing diagnoses.
3.2.3 - SUMMARY OF RESULTS
945 patients with hip DXA scans and 1,130 patients with lumbar spine DXA scans 
were included in the final analysis (Tables 6 and 7). The population sample was 
predominantly female (hip scans; normonatremia 85.7%, mild hyponatremia 
84.5%). Mean length of exposure ranged between 12.97 quarters (Table 7, mild 
hyponatremia, spine scans) and 14.33 quarters (Table 6, normonatemia, hip scans) 
on average for the two scan categories, with sodium measurements available in 77% 
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to 80% of quarters. In the group of hip scans, hyponatremia was present in 58 
patients (6.2%), while the condition was present in 58 of the lumbar spine scans 
(5.1%). Patients with “mild hyponatremia” were significantly older (Table 7, hip 
scans; 67.36 ± 10.12 vs 62.48 ± 11.97 years), weighted less (Table 7, hip scans; 
64.54 ±15.57 vs 69.01 ±15.11 kg) and had higher use of opioids, sedatives, beta-
receptor antagonists, selective serotonin reuptake inhibitors and glucocorticoids. 
Patients with “mild hyponatremia”, with the exception of intertrochanteric BMD, 
presented with significantly lower BMC and BMD values at all regions of the hip 
compared to normonatremic patients (Table 8, total hip BMD 0.722 ± .120 vs. 0.785 
± 0.137 g/cm2,p < .05). In the lumbar spine, “mild hyponatremia” was associated 
with lower BMD in L1 and total lumbar spine (Table 9, 0.817 ± 0.171 vs 0.846 ± 
0.155 g/cm2,p < .05) at baseline. At follow-up, patients with “mild hyponatremia” 
progressed with greater absolute loss of trochanteric BMC (−0.234 ± 0.784 vs 
0.2247 ± 2.999, p < .05) and BMD, femoral neck BMD (−0.014 ± 0.042 vs 0.0143 ± 
0.164*, p < .05), annualized femoral neck BMC (−2.3% ± 8.8%* vs. 2.4% ± 
33.5%*, p < .05) and absolute total hip BMD (−0.012 ± 0.045 vs. 0.0122 ± 0.173, p 
< .05) (Table 10). In the lumbar spine, adjusted absolute losses of L1 BMC (−0.407 
± 0.337 vs. 0.389 ± 0.33, p < .05), L3 BMC (−0.384 ± 0.329 vs. 0.335 ± 0.323, p < 
.05) and L4 BMC (−0.488 ± 0.426 vs. 0.490 ± 0.418, p < .05) were greater for 
patients with “mild hyponatremia” (Table 11).
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Gender (% female) 85.7% 84.5%
Age at baseline (years) 62.48 ± 11.97* 67.36 ± 10.12*
Weight at baseline (kg) 69.01 ± 15.11* 64.54 ± 15.57*
Height at baseline (cm) 164.13 ± 8.40 162.12 ± 7.27
Calculated BMI at baseline (kg/m2) 25.53 ± 4.74 24.47 ± 5.28
Observation period (months) 43.00 ± 16.25 39.32 ± 14.05
Section 2: biochemical data
Number of sodium measurements 9.77 ± 17.68* 23.6 ± 30.50*
Quarters of observations 14.33 ± 5.42 13.11 ± 4.68
Quarters with at least one sodium 
measurement
9.86 ± 2.84 9.88 ± 2.84
Fraction measurements/observations 
quarters
.73 ± .21 .78 ± .21
Mean HBA1C IFCC (mmol/mol) 38.65 ± 3.39 (n = 
343)
39.16 ± 3.58 (n = 
37)
Lower 95% CI of mean sodium 
during observation
139.32 ± 1.35* 133.10 ± 1.54*
Upper 95% CI of mean sodium 
during observation
141.53 ± 1.55* 135.54 ± 1.20*
*: p < .05
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Gender (% female) 84.9% 86.4%
Age at baseline (years) 62.18 ± 11.80* 67.65 ± 10.09*
Weight at baseline (kg) 68.64 ± 14.32* 64.18 ± 15.04*
Height at baseline (cm) 164.69 ± 8.31 162.63 ± 7.64
Calculated BMI at baseline (kg/m2) 25.23 ± 4.50 24.18 ± 5.04
Observation period (months) 41.42 ± 15.81 38.90 ± 13.52
Section 2: biochemical data
Number of sodium measurements 10.74 ± 19.00* 24.06 ± 29.10*
Quarters of observations 13.81 ± 5.27 12.97 ± 4.51
Quarters with at least one sodium 
measurement
10.04 ± 2.66 10.12 ± 2.81
Fraction measurements/observations 
quarters
.77 ± .21 .80 ± .20
Mean HBA1C IFCC (mmol/mol) 38.51 ± 3.59* (n = 
412)
39.08 ± 3.53 (n = 
40)
Lower 95% CI of mean sodium 
during observation
139.45 ± 1.43* 132.97 ± 1.62*
Upper 95% CI of mean sodium 
during observation
141.71 ± 1.64* 135.38 ± 1.28*
*: p < .05
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*: p < .05
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*: p < .05
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Change in trochanteric BMC, absolute 
units
0.2247 ± 2.999* −0.234 ± 0.784*
Change in trochanteric BMC, % 
annualized
3.0% ± 44.8%* −3.2% ± 11.7%*
Change in trochanteric BMD, 
absolute units
0.0143 ± 0.164* −0.014 ± 0.042*
Change in trochanteric BMD, % 
annualized
2.5% ± 29.0%* −2.6% ± 7.6%*
Change in intertrochanteric BMC, 
absolute units
0.1630 ± 6.608 −0.134 ± 1.729
Change in intertrochanteric BMC, % 
annualized
0.6% ± 32.0% −0.4% ± 8.6%
Change in intertrochanteric BMD, 
absolute units
0.0122 ± 0.219 −0.012 ± 0.057
Change in intertrochanteric BMD, % 
Annualized
1.2% ± 25.5% −1.2% ± 6.7%
Change in femoral neck BMC, 
absolute units
0.0800 ± 1.176 −0.078 ± 0.307
Change in femoral neck BMC, % 
annualized
2.4% ± 33.5%* −2.3% ± 8.8%*
Change in femoral neck BMD, 
absolute units
0.0131 ± 0.177* −0.012 ± 0.046*
Change in femoral neck BMD, % 
annualized
2.2% ± 27.7%* −2.1% ± 7.2%*
Change in Ward's triangle BMC, 
absolute units
0.0066 ± 0.330 −0.004 ± 0.086
Change in Ward's triangle BMC, % 
annualized
2.7% ± 101.2% −2.3% ± 26.4%
Change in Ward's triangle BMD, 
absolute units
0.0075 ± 0.240 −0.005 ± 0.062
Change in Ward's triangle BMD, % 
annualized
3.0% ± 98.8% −2.7% ± 25.9%
Change in total hip BMC, absolute 
units
0.4678 ± 8.869 −0.446 ± 2.320
Change in total hip BMC, % 
annualized
1.4% ± 29.4% −1.3% ± 7.7%
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Change in total hip BMD, absolute 
units
0.0122 ± 0.173* −0.012 ± 0.045*
Change in total hip BMD, % 
annualized
1.6% ± 23.5% −1.6% ± 6.2%
*: p < .05
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Change in L1 BMC, absolute 
units
0.389 ± 0.33* −0.407 ± 0.337*
Change in L1 BMC, % 
annualized
4.1% ± 3.7% −4.2% ± 3.8%
Change in L1 BMD, absolute 
units
0.016 ± 0.020 −0.015 ± 0.020
Change in L1 BMD, % 
annualized
2.1% ± 3.0% −2.0% ± 3.0%
Change in L2 BMC, absolute 
units
0.240 ± 0.293 −0.221 ± 0.299
Change in L2 BMC, % 
annualized
1.6% ± 2.8% −1.5% ± 2.8%
Change in L2 BMD, absolute 
units
0.011 ± 0.015 −0.010 ± 0.016
Change in L2 BMD, % 
annualized
1.2% ± 2.0% −1.1% ± 2.0%
Change in L3 BMC, absolute 
units
0.335 ± 0.323* −0.384 ± 0.329*
Change in L3 BMC, % 
annualized
2.5% ± 2.5% −2.8% ± 2.5%
Change in L3 BMD, absolute 
units
0.014 ± 0.016 −0.014 ± 0.016
Change in L3 BMD, % 
annualized
1.5% ± 2.0% −1.6% ± 2.0%
Change in L4 BMC, absolute 
units
0.490 ± 0.418* −0.488 ± 0.426*
Change in L4 BMC, % 
annualized
3.1% ± 2.8% −3.0% ± 2.8%
Change in L4 BMD, absolute 
units
0.017 ± 0.018 −0.017 ± 0.018
Change in L4 BMD, % 
annualized
1.7% ± 2.1% −1.7% ± 2.1%
Change in total lumbar spine 
BMC, absolute units
1.186 ± 1.114 −1.226 ± 1.136
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Change in total lumbar spine 
BMC, % annualized
2.4% ± 2.8% −2.4% ± 2.9%
Change in total lumbar spine 
BMD, absolute units
0.013 ± 0.013 −0.013 ± 0.013
Change in total lumbar spine 
BMD, % annualized
1.5% ± 1.6% −1.4% ± 1.6%
*: p < .05
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3.3 - PAPER 3
3.3.1 - MATERIALS AND METHODS
3.3.1.1 - DESIGN
This paper was a retrospective matched cohort study examining the weekly risk of 
fracture occurrence on thiazide-use versus non-use in Danish patients. The work 
also sought to investigate patterns of thiazide prescription in Danish patients.
3.3.1.2 - REGISTRIES AND EXPOSURE VARIABLES
3.3.1.2.1 - NATIONAL DANISH PATIENT REGISTRIES
Multiple tables from the National Danish Patient Registry were used to conduct this 
study. The original data source comprised approximately 3.1 million Danish 
citizens; 1.6 million men, women and children who had at one point sustained a 
fracture, and 1.5 million propensity matched individuals who had never sustained a 
fracture at the date the sampling was performed. Data were available from between 
January 1st 1996 and December 31st 2011. From the originating 3.1 million 
individuals, data between January 1st 1977 and December 31st 2011 were extracted 
regarding prescription use, hospital admissions and hospital outpatient visits, yearly 
socioeconomic status, migration and mortality. Prescription data consisted of all 
reimbursed prescriptions included date of reimbursement, ATC code, pack size and 
both numerical and WHO-defined daily dose equivalent. Patient diagnoses were 
gathered from the Danish National Hospital Discharge Register and consisted of 
date of diagnosis, ICD-10 code and contact category (i.e. admission or outpatient 
visit). Migration data consisted of date of immigration/emigration and country of 
origin/destination. Mortality data consisted of date of death, cause of death and 
causal diagnosis when applicable. 
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3.3.1.2.2 - THE STUDIED POPULATION
Initially, all prescriptions of thiazide diuretics were selected based on the ATC code 
C03AB. Grouping individuals by social security number (“CPR”), prescription 
reimbursements were sorted and ranked by date of collection (earliest to latest). 
Based on pack size, number of packs and DDD, and assuming consumption of one 
DDD per day, each prescription was reconstructed to an approximate stop date. 
Each prescription was prolonged by 20% to account for possible non-compliance 
and time lag to collection of a new prescription. By the ranked dates, data were 
transposed and overlaps between prescriptions used to prolong the earliest 
prescription. From the resulting periods, a washout period of 14 days was deemed 
necessary for a new thiazide exposure period to commence, otherwise the two 
periods were merged to one. The resulting periods were ranked by number for each 
individual, and based on the start date of each exposure period, each thiazide-
exposed individual was matched with control individuals by exact birthdate and sex. 
The control individuals were then excluded if they were exposed to thiazides during 
the shared observation time.  For each individual and each date, a “run-in” period of 
52 weeks before the start of observations was constructed. Fracture occurrence for 
each individual was established using ICD-10 diagnoses; spinal fractures (DM484, 
DM485, DM485A, DM495, DM809C, DS32, DS320, DS320A, DS320B, DS320C, 
DS320D, DS320E, DS327, DS327A, DS328, DS328A, DS220, DS221 and DT08), 
hip and femoral region (DM809B, DS72, DS720, DS721, DS721A, DS721B, 
DS722, DS723, DS724B, DS724C, DS727, DS728A and DS729), wrist and hand 
(DM809A, DS52, DS521A, DS521B, DS522, DS523, DS524, DS525, DS525A, 
DS525B, DS525C, DS526, DS527, DS528, DS528A, DS528B, DS528C, DS529, 
DS620 and DS621) and proximal upper arm and shoulder fractures (DS422, 
DS422A, DS422B, DS422C, DS423, DS423A, DS424 and DS427). Time in weeks 
from observation start to fracture occurrences were calculated, and from this, it was 
established categorically if a fracture occurred during each week or not. Individuals 
were followed for up to 15 years with weeks excluded from the analysis in case of 
loss-to-follow up, migration or mortality. For each week, odds ratio of fracture 
occurrence was calculated using logistic regression between exposed and non-
exposed individuals; crude and adjusted for thiazide exposure length, prior thiazide 
exposure, pre-existing diagnoses and medication use. During the periods of the run-
in period, weeks 0-42 and from 43 to the end of the study, incidence rates and 
incidence rate ratios were calculated, both crude and age-adjusted.
3.3.2 - STATISTICAL ANALYSIS
Descriptive statistics included mean, SD and range for numerical variables. 
Independent samples t-tests were performed between “thiazide exposure” and 
“thiazide non-exposure” for numerical values with the exception of CCI scores 
where Mood’s median test was performed. Incidence rates and incidence rate ratios 
were calculated from number of events divided by observation time.
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3.3.3 – SUMMARY OF RESULTS
A total of 1,602,141 thiazide exposure periods and 1,530,233 matched non-exposure 
periods were eligible for inclusion (Table 12). In total, 468,271 individuals with 
thiazide exposure and 655,399 users of non-exposure were included. At the start of 
exposure, thiazide exposed individuals were significantly older (69.47 ±13.97 vs. 
69.17 ±14.07 years, p < .05), more likely to be female (OR 1.04 [1.03;1.04] vs 0.97 
[.96;.97], p < .05) and presented with lower yearly salaries (205,274.20 ±182,021.28 
vs. 226,118.41 ±242,711.14, DKK, p < .05) compared to non-users (Table 12). 
Thiazide users had higher concurrent use of other antihypertensive agents, 
glucocorticoids, insulin, thyroid hormone supplements and antiresorptive agents. 
Thiazide-exposed individuals were more likely to have existing cases of cerebral 
stroke (OR 1.13 [1.12-1.14]), hypertension (OR 2.82 [2.80; 2.84]), ischemic heart 
disease (OR 1.07 [1.06-1.07]), osteoporosis (OR 1.05 [1.04; 1.06]) and diabetes 
mellitus type 2 (OR 1.02 [1.01; 1.03]). During the majority of the 52-week run-in 
period, thiazide exposure was associated with higher OR during each week (Figure 
1). From weeks 0 to 42 after commencing thiazide exposure, OR was increased with 
thiazide exposure and a simple moving average showed an increasing trend (Figure 
1). After week 43, fracture risk progressively declined until weeks 116 where 
sporadic weeks of lower risk were observed (Figure 1). Overall adjusted incidence 
rate ratios increased from the run-in period (age-adjusted IRR 1.44 [1.42; 1.47]) to 
the week-0-to-42 period (age-adjusted IRR 1.27 [1.24; 1.29]), then further decreased 
during the week-43-to-780 period (age-adjusted IRR 1.14 [1.11; 1.18]) (Table 13).
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Table 12: Descriptive data, epidemiological data, and medication exposure during 
the observation period (in DDD per day) for C03AB alone
Thiazide exposure














Age at beginning 
of exposure 
period, years
69.47 (13.97) 69.17 (14.07) 0.000* [0.27; 
0.33]
Gender (female), 
odds ratio [95% 
CI]
1.04 [1.03; 1.04] 0.97 [.96; .97] 0.000*
Yearly income 




























5.39 (7.08) 1.07 (0.69) 0.000* [4.31; 
4.33]





77.05 (117.68) 34.33 (153.53) 0.000* 
[42.42; 
43.02]





204.69 (520.18) 2808.80 (1785.98) 0.000* 
[2601.23; 
2606.99]
Total number of 
days of thiazide 
exposure in 







Total number of 





562.00 (778.48) 2833.62 (1770.48) 0.000* 
[2268.62; 
2274.61]
Number of days 
since end of last 
thiazide exposure 
period




0 344.946 (21.5%) 304.650 (19.3%)
1–2 461.992 (28.8%) 481.500 (30.6%)
3–4 605.512 (37.8%) 585.547 (37.2%)
5–6 157.177 (9.8%) 148.726 (9.4%)
>6 32.514 (2.0%) 54.630 (3.5%)
Median Charlson 
Index score (IQR)
2 (3) 3 (3) 0.000*
*: p < .05
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Table 13: Incidence rates and incidence rate ratios for fracture occurrence: 





























Figure 1: Adjusted weekly odds ratios (ORs) for risk of fracture occurrence for thiazide 




3.4 - PAPER 4
3.4.1 - MATERIALS AND METHODS
This paper was a retrospective matched cohort study examining the 10-year risk of 
fracture occurrence when commencing thiazide diuretics at certain ages versus non-
users, in order to investigate if certain age groups show different risks of thiazide-
related fractures or fracture protection.
3.4.1.1 - REGISTRIES AND EXPOSURE VARIABLES
3.4.1.1.1 - NATIONAL DANISH PATIENT REGISTRIES
Data originated from the National Danish Patient Registry and comprised of 
approximately 2.93 million Danish citizens between January 1st 1996 and December 
31st 2011. We reused prescription data, patient diagnoses data, socioeconomic data, 
mortality data and migration data. 
3.4.1.1.2 - THE STUDIED POPULATION
Patients were selected initially as “thiazide users” if they at one point had collected 
a prescription for thiazide diuretics. Two separate analyses were performed for ATC 
categories C03AB (“thiazides with potassium supplementation”) and C03AA 
(“thiazides, plain”) and C03AB (“thiazides with potassium supplementation”) 
combined. The start date was defined as the date the first thiazide prescription was 
collected. Similar to the technique in “paper 3”, thiazide exposure periods were then 
reconstructed based on collection dates, pack size, DDD and prolongation of 20% to 
account for non-compliance and time lag to prescription collection. Age and sex 
were established at the individual start dates and females above 50 years of age 
included for further analysis. Exposure periods between January 1st, 1999 and 
December 31st 2001 were included. Thiazide-exposed individuals were matched by 
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sex and exact birthdates to individuals who had never been exposed to thiazides. 
Fracture occurrence was defined as one patient diagnosis of spinal fractures (M484, 
M485, M485A, M495, M809C, S32, S320, S320A, S320B, S320C, S320D, S320E, 
S327, S327A, S328, S328A, S220, S221, and T08), hip and femoral region fractures 
(M809B, S72, S720, S721, S721A, S721B, S722, S723, S724B, S724C, S727, 
S728A, and S729), wrist and hand fractures (M809A, S52, S521A, S521B, S522, 
S523, S524, S525, S525A, S525B, S525C, S526, S527, S528, S528A, S528B, 
S528C, S529, S620, and S621) or proximal upper arm and shoulder fractures (S422, 
S422A, S422B, S422C, S423, S423A, S424, and S427) occurring within 10 years of 
the observation start. Lost to follow-up was defined as dates of death, date of 
emigration, 10-year observation or December 31st 2011, whichever came first. 
Medication use in DDD from January 1st 1996 to the start of observation, and from 
the start to end of observation were calculated. Categorical presence of 
comorbidities associated with increased risk fractures at the start of observation was 
established.  Grouped by absolute age in years, floored to the nearest integer, Cox 
proportional hazards models were constructed for 10-year fracture risk both crude 
and adjusted for fracture-prone medication use, treatment length, CCI and Boolean 
comorbidity presence. A secondary analysis of 10-year fracture occurrence after 
discontinuation of thiazide diuretics compared to non-users was performed using the 
same methodology and adjustments.
3.4.2 - STATISTICAL ANALYSIS
Descriptive statistics included mean, SD and range for numerical variables. Median 
and interquartile ranges were calculated for ordinal variables. Independent samples 
t-tests were performed between “thiazide exposure” and “thiazide non-exposure” for 
numerical values with the exception of ordinal variables where Mood’s median test 
was used. Chi-square (χ2) analysis with calculation of odds ratio was used for 
categorical data. Cox proportional hazard models were used as time-to-event 
analyses with estimation of hazard ratios.
3.4.3 - SUMMARY OF RESULTS
58,790 females above 50 years of age were included versus 1,357,829 non-exposed 
matched individuals (Table 14). Thiazide-exposed individuals were significantly 
older as a whole (71.99 ± 11.22 vs. 69.80 ±11.44, p < .05), had higher median CCI 
scores (3 (IQR 4) vs. 2 (IQR 3), p < .05) and higher prior use of analgesics, 
sedatives, cardiovascular medication, antidepressants and antiresorptive agents than 
non-exposed individuals. Thiazide-exposed individuals were also more likely to 
have existing hypertension and stroke, but less likely to have chronic kidney 
disease, Parkinson’s disease and chronic obstructive pulmonary disease (Table 15). 
The age-grouped Cox regression models revealed increased 10-year HR of fracture 
occurrence for C03AB when exposure began at and after age 73 years, lasting until 
age 96, compared to non-users (Figure 2). From 76 years upwards, a trend towards 
increasing risk year by year was found (Figure 2). Between ages 50 and 73, risks 
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were comparable and sporadically increased with thiazide exposure. Discontinuing 
thiazide therapy between the ages of 63 and 97 showing a trend towards decreasing 
10-year crude HR of fracture compared to non-users (Figure 3). Between ages 50 




Table 14: Descriptive data, epidemiological data, and medication exposure during 

















Hip and pelvic fractures 7.042 (12.0 %) 114.539 (8.4 %) p<0.05*





Spinal fracture 1.076 (1.8 %) 16.088 (1.2 %) p<0.05*
Upper extremity fracture 3.852 (6.6 %) 70.043 (5.2 %) p<0.05*
Wrist Fracture 4.664 (7.9 %) 112.724 (8.3 %) p<0.05*
CCI
0 16.381 (27.9 
%)
296.475 (21.8 %)
1–2 11.964 (20.4 
%)
384.313 (28.3 %)
3–4 26.843 (45.7 
%)
573.826 (42.3 %)
5–6 3.218 (5.5 % 83.247 (6.1 %)
>6 384 (0.6 %) 19.968 (1.5 %)
Median CCI (IQR) 3 (4) 2 (3) p<0.05*
Previous exposure and 
absent exposure of thiazide 
diuretics
p<0.05*
Avg. no of days of “thiazide 









Avg. no of days of “thiazide 



























0 (0) (0) 
(1,357,829)
p<0.05*




1 (0) (0) 
(1,357,829)
p<0.05*




0 (0) (0) 
(1,357,829)
p<0.05*
*: p < .05
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Table 15: Co-morbidity for underlying individuals exposed to C03AB at the 
beginning of the observation period. OR for preexisting diagnoses
Cases
OR, 95 % CI, p 
value
Conditions of higher OR among exposed individuals
 Angina pectoris (I20) 1.23 [1.17; 1.29], 
p<0.05*
 Cerebral infarction (I63) 1.08 [1.00; 1.18], 
p<0.05*
 Essential (primary) hypertension (I10) 1.89 [1.80; 1.98], 
p<0.05*
 Fracture at wrist and hand level (S62) 1.14 [1.07; 1.21], 
p<0.05*
 Fracture of forearm (S52) 1.09 [1.05; 1.13], 
p<0.05*
Conditions of lower OR among exposed individuals
 Anemia, unspecified (D649) 0.83 [0.76; 0.91], 
p<0.05*
 Chronic ischemic heart disease (I25) 0.87 [0.82; 0.91], 
p<0.05*
 Chronic kidney disease, unspecified (N189) 0.25 [0.17; 0.37], 
p<0.05*
 Chronic obstructive pulmonary disease with 
(acute) exacerbation (J441)
0.82 [0.75; 0.89], 
p<0.05*
 Fracture of femur (S72) 0.82 [0.79; 0.86], 
p<0.05*
 Heart failure (I50) 0.50 [0.47; 0.54], 
p<0.05*
 Other chronic obstructive pulmonary disease 
(J44)
0.86 [0.82; 0.91], 
p<0.05*
 Parkinsons sygdom (G209) 0.61 [0.52; 0.72], 
p<0.05*
 Type 1 diabetes mellitus (E10) 0.92 [0.84; 0.99], 
p<0.05*
 Type 2 diabetes mellitus (E11) 0.91 [0.86; 0.97], 
p<0.05*
 Unspecified dementia with behavioral disturbance 
(F039)
0.73 [0.66; 0.80], 
p<0.05*
*: p < .05
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3.5 - PAPER 5
Kruse C, Goemaere S, de Buyser S, Lapauw B, Eiken P, Vestergaard P. 
Predicting Mortality and Incident Immobility in Older Belgian Men by 
Characteristics Related to Sarcopenia and Frailty. 
Submitted 2017 July to Osteoporosis International, In Review
3.5.1 - MATERIALS AND METHODS
3.5.1.1 - DESIGN
This study was a retrospective cohort study using data on older Belgian men. The 
purpose of the study was to investigate the predictability of 5-year mortality and 3-
year incident immobility in this patient group based on DXA scans, physical 
performance, blood samples and gerontology battery tests. An aim was to rank 
predictor importance of the same outcomes to assess the relative importance of 
hyponatremia and thiazides.
3.5.1.2 - DATA SOURCES AND EXPOSURE VARIABLES
3.5.1.2.1 - THE MERELBEKE STUDY
This study used data from the Merelbeke Study which was anchored at Gent 
University Hospital in Gent, Belgium210. From 1996 onwards, the study collected 
data on a cohort of older Belgian men from a semi-rural province of Merelbeke 
(population 20,000) for several purposes, primarily to investigate the effect of 
andropause and androgens on mortality and bone health. All men between ages 70 
to 85 years were invited by mail. Between 1996 and 2000, annual visits took place 
for all participants with another follow-up in 2003. Annual statuses of mortality 
have since been collected via telephone calls to patients and relatives. The scope of 
the yearly visits varied, but could consist of blood and urine samples, whole-body 
and bone DXA scans (forearm, lumbar spine and hip), gerontology battery tests (e.g. 
SF-36211, RDRS-2212, GDS213) and physical tests (TGUG214, handgrip strength), 
alongside collection of comorbidity and medication use information.
3.5.1.2.2 - THE STUDIED POPULATION
This work centered around the second annual visit in 1997 where the majority of 
tests were undertaken for all individuals. Further exposure variables that were only 
collected in 1996 and considered stable, i.e. height and weight, were included. The 
date of the second visit was used as start of observation and for each individual, all 
measurements of blood samples, all separate answers to the gerontology battery 
tests, all recorded performances of the physical tests and all BMC and BMD 
measurements from the performed DXA scans were selected for each individual. 
Two outcomes were defined; 1) 5-year mortality, and 2) 3-year incident severe 
67
67
immobility based on subjective reporting from the SF-36 questionnaire (from “no” 
to “yes” when answering one of two questions, 3E; “Are you limited in coping a 
flight of stairs?”, and 3H; “Are you limited in talking several blocks?”). A 
systematic machine learning procedure was used to assess predictability of different 
models on unseen data samples, followed by extraction of ranked predictor 
importance for the final model. Descriptive analysis of mortality versus non-
mortality, and of included versus non-included patients, were performed.
3.5.1.2.3 - THE MACHINE LEARNING PROCEDURE.
The separate datasets for the two outcomes were split into “training” (75% of data 
points) and “test” (25% of data points) datasets, by balanced outcome proportion in 
the four groups. Across all model types, k-5, 10-repeat cross-validation was used 
across the scope of hypercomplexity parameters for each model to assess the 
complexity with which the highest AUC was attained. A total of 29 model types 
were trained: parametric models, non-parametric models, tree-based with boosted 
and bagged versions of the same. For models requiring complete cases, random 
forest imputation was used through 1,500 trees and 5 iterations. Ranked predictor 
importance based on error reduction capability and hierarchical presence were 
extracted from the best performing model. To assess optimal cut-off values for the 
resulting predictors, classification tree models were trained across all data points 
with these sole predictors.
3.5.2 - STATISTICAL ANALYSIS
Descriptive statistics included mean, SD and range for numerical variables. Median 
and 25th-75th percentiles were calculated for non-parametric data. Welch tests were 
performed between “mortality” and “non-mortality”/”survival” for numerical values 
with the exception of ordinal variables where a Wilcoxon rank sum test was used. 
Data distributions were assessed by QQ-plots, histograms and kernel smoothing. 
Chi-square (χ2) analyses with calculation of odds ratios were used for categorical 
data.
3.5.3 - SUMMARY OF RESULTS
352 men formed the original Merelbeke cohort in 1996 (participation rate 47.1%). 
In this study, 264 subjects were included from the visit in 1997. For the mortality 
outcome, 56 mortalities occurred within five years (21.2%) (Table 16). In the 
mortality group, subjects were significantly older (77.98 ± 4.54 years versus 75.61 ± 
3.55), had lower intertrochanteric BMD and T-score, lower trochanteric BMD, 
higher TGUG duration in seconds and higher RDRS-2 scores (Table 16). The best 
predictive model type of this outcome was a Bayesian generalized linear model with 
a test AUC of .85 [.73 ; .97], a sensitivity of 78% and a specificity of 89% at a 
Youden probability cut-off of 22.3%. Ranked predictor importance revealed that 
plasma 25-hydroxycholecalciferol, plasma albumin, trochanteric BMD and T-scores 
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and total hip region BMD to be the best predictors of mortality (Table 17). Serum 
sodium and thiazide use did not figure in the most important predictors. For the 
outcome “incident immobility”, 39 subjects became severally immobile over a 3-
year period, while 102 remained mobile (outcome rate 27.7%).  The best performing 
model was the multivariate adaptive regression splines model with a test AUC of 
.74 [.57;.91], a sensitivity of 67% and a specificity of 78% at a Youden probability 
cut-off of 14.2%. The most important predictors for this outcome were SF-36 
Physical Domain Numerical Score, BMI, SF-36 Physical Domain Standardised 
Score, IPSS-35 Total Score, plasma SHBG levels, plasma testosterone and GDS 
Question 1 Numerical Score (Table 17). Nor serum sodium nor thiazide use figured 




Table 16: Descriptive data. grouped by 5-year mortality vs. survival
Mortality
n = 56 (21.2%)
Survival 










Age (years) 77.98 ±4.54 75.61 ±3.55 ***
Height (cm) 168.1 ±7.5 167.9 ±6.0
Weight (kg) 72.3 ±13.7 75.0 ±11.3
BMI (kg/m2) 25.47 ±3.97 26.55 ±3.32 *
Biochemistry 
Creatinine, Serum 
(mol/L) 1.26 ±.34 1.22 ±.2
Natrium, Serum 
(mmol/L) 141.02 ±3.29 141.61 ±2.35
Creatinine, Urine 
(mg/dL) .95 ±.5 1.11 ±.46 *
Natrium, Urine 
(mmol/L) 85.54 ±52.4 94.79 ±48.06
DXA, Hip
Lowest T-score. 
hip/femoral neck (SD) -1.81 ±.9 -1.42 ±.86 **
Total, BMC (g) 41.25 ±8.69 44.75 ±8.15 **
Total, BMD (g/cm2) .86 ±.15 .94 ±.14 ***
Total, Z-Score (SD) -.14 ±1.02 .26 ±.93 **
Femoral Neck, BMC 
(g) 4.4 ±.86 4.71 ±.81 **
Femoral Neck, BMD 
(g/cm2) .69 ±.12 .74 ±.12 **
Trochanteric Region, 
BMC (g) 8.99 ±2.07 10.13 ±2.05 ***
Trochanteric Region, 
BMD (g/cm2) .65 ±.12 .72 ±.12 ***
Intertrochanteric 
Region, BMC (g) 27.86 ±6.32 29.91 ±5.84 *
Intertrochanteric 
Region, BMD (g/cm2) 1.0 ±.19 1.1 ±.17 ***
Ward’s Triangle, 
BMC (g) -2.59 ±.77 -2.23 ±.77 **
Ward’s Triangle, 






(seconds) 14.4 ±7.21 11.15 ±3.16 ***
Grip Strength, 
Smedley, Maximum 
(kg) 28.36 ±7.49 30.91 ±7.55 *
Balance Test
- Completed 6/6 (n, 
%) 10 (17.8%) 74 (35.9 %)
- Completed <6 (n, %) 46 (82.2%) 132 (64.1 %)
**
Cognitive Function
RDRS-2, Total Score 21 (20-23) 20 (19-21) ***
GDS, Total Score 6 (3-9.75) 4 (2-7) **
SF-36, Total Score 74 (62.75-78.25) 77 (68.75-81.25) *
Sarcopenia 
Consensus Variables
Janssen BIA Predicted 
Absolute Muscle 
Mass (kg) 17.85 ±3 18.87 ±2.01 **
SMI, Predicted from 
Janssen BIA (kg/m2) 10.25 ±1.61 10.74 ±1.17 *
*: p < .05. **: p < .01. *** p < .001 
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Table 17: Ranked Variable Importance for the 5-Year Mortality Outcome 
Predicted Using a Bayesian Generalized Linear Model
Ra
nk
























2. Plasma albumin 
(g/L)







4. DXA: Hip 
Trochanteric T-
Score (SD)
88 -1.56 35/17 172/28





6. DXA: Hip Total 
T-Score (SD)
87 -1.12 74/27 133/18






8. DXA: Hip 
Intertrochanteric 
T-Score (SD)
86 -1.49 39/17 168/28
9. Lean Body Mass 
(%)




83 6.48 g 7/1 200/39
11. Balance Score 82 N/A N/A N/A
12. SF-36: 11A 
Scorea




79 -.91 34/16 170/28








15. DXA: Ward’s 
Triangle T-Score 
(SD)
79 -2.80 53/20 154/25





17. DXA: Lower 
Arm T-Score 
(SD)
78 -3.49 31/15 178/30





19. DXA: Radius T-
Score (SD)







*: Variable importance by predictor presences across ensembled tree-models 
weighted by reduction in error, then normalized to 0-100.
a: “I become ill more frequently than my peers”
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Table 18: Ranked Variable Importance for the Incident Immobility Outcome 





































68 37.5 10/2 104/24
4. IPSS-35 
Total Score















22 N/A N/A N/A
a: “Are you basically satisfied with your life?”
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3.6 - PAPER 6
Kruse C, Eiken P, Vestergaard P.
Hyponatremia is Associated with Greater Hospital Length of Stay and Cost of Stay 
in Danish patients. 
Submitted 2017 July to Journal of General Internal Medicine
3.6.1 - MATERIALS AND METHODS
3.6.1.1 - DESIGN
This paper was a retrospective cohort study examining LoS, CoS and readmission 
risk for hospitalized patients relative to nadir serum sodium values during the 
hospitalizations.
3.6.1.2 - REGISTRIES AND EXPOSURE VARIABLES
For this study, a combination of regional biochemical sample databases and national 
Danish patient registries were used, identical to “paper 1”, with no updates to data 
since publication.
3.6.1.2.1 - REGIONAL BIOCHEMICAL SAMPLES DATABASE
The biochemical samples database was the same as the one used in “paper 1” with 
no updates since time of publication, extracted from the list of scanned patients. The 
data comprised biochemical samples for all patients who had at one point been in 
contact with the Department of Endocrinology at Aalborg University Hospitals in 
Denmark. Data spanned 1996 to 2012 and was extracted from the Department of 
Biochemistry at Aalborg University Hospital, a DANAK certified institution 
(Appendix 9).
3.6.1.2.2 - NATIONAL DANISH PATIENT REGISTRIES
Data on prior prescription reimbursement, patient diagnoses, mortality and 
migrations were collected from the National Danish Patient Registry. Further 
database tables of primary healthcare sector use on the same patients were also 
utilized. Further data on hospital admissions costs between January 1st 2007 and 
December 31st 2010 were included.
3.6.1.3 - THE STUDIED POPULATION
Primary inclusion in this study were all individuals with at least one hospitalization, 
regardless of ICD-10 diagnosis code, who had had at least one blood sample drawn 
within the administrative Region of North Denmark. Based on a selected list of 
admission codes from the ICD-10 registry, dates of admission and discharge were 
selected with overlaps resulting in prolongation of the observation periods. 
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Admissions were only included if they had taken place in the administrative Region 
of North Denmark. After the date of discharge, a further follow-up date (“post 
period”) was selected at the first occurring readmission, emigration, mortality or one 
year after the date of discharge. Dichotomous readmission within 30 days was 
established. From the table of hospital admissions costs related to specific 
admissions, the total monetary costs in DKK were calculated for both the 
hospitalization itself and the following convalescence. The nadir sodium value, the 
sodium value closest to admission and closest to discharge were selected of either 
arterial, venous or capillary origin. From the date of admission and one year prior, 
the total reimbursed dosage of certain pharmaceuticals and presence of specific 
comorbidities were computed. During the follow-up period, monetary primary 
sector expenses were computed for GP visits, emergency GP services, dental 
services, podiatrists and physical therapy. Admissions were grouped as 
“hyponatremia” (serum sodium below 137 mmol/L), “normonatremia” ([Na+] 137-
147 mmol/L) and “not measured” if no sodium samples were drawn. LoS and 
readmission within 30 days were established.
3.6.2 - STATISTICAL ANALYSIS
Descriptive statistics included mean, SD and range for numerical variables. Median 
and 25th-75th percentiles were calculated for non-parametric data. Welch T-tests with 
Bonferroni correction were performed between “hyonatremia”, “normonatremia” 
and “not measured” for numerical values with the exception of ordinal variables 
where Wilcoxon rank sum tests were used. Pairwise G-tests with Holm correction 
were performed for categorical data between “hyonatremia”, “normonatremia” and 
“not measured”.
Linear regression models of 1) nadir sodium to length of stay, 2) nadir sodium to 
cost of stay were fitted for crude relationships and with adjustments for sex, age 
(years) at admission, CCI total score and reimbursed total DDD doses of 
pharmacologic agents, i.e. DPP-4 inhibitors (A10BH), thiazides and potassium in 
combination (C03AB), ARBs (C09CA), glucocorticoids (H02AB), hydantoin 
derivatives (N03AE) and SSRIs (N06AB). Linear models were fitted to both the 
entire data and group-wise for each primary ICD-10 diagnosis. Logistic regression 
models were fit both for crude and adjusted models (also for factors above) between 
nadir sodium and 30-day risk of readmission. Multiple comparisons were adjusted 
with Bonferroni correction.
3.6.3 - SUMMARY OF RESULTS
The original data sources comprised 32,392 patients. Following selection by 
inclusion criteria, 9,912 individuals with at least one inpatient hospitalization and 
one blood sample were identified between January 1st 2007 and December 31st 2010 
(Table 19). In the final analysis, 1,612 individuals with a total of 5,809 admissions 
and readmissions were included for the examined diagnoses. Hyponatremia by nadir 
sodium occurred in 919 (15.8%) of admissions, normonatremia was present in 1,593 
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(27.4%) while no sodium measurements were drawn in 3,297 (56.7%). The mean 
age of hyponatremic patients was 69.01±12.43 years (vs. 69.04±12.61 year for 
normonatremia, not significant), 67.5% were female (vs. 68.2%, not significant) and 
the average LoS was 12.10 ±12.23 days (vs 8.27±8.97, p < .001) (Table 19). The 
mean nadir sodium value was 132.8 ±3.2 mmol/L. Hyponatremic subjects had high, 
but lower CCI scores than normonatremic subjects (median 11 (25th pct. 8; 75th pct. 
14) vs. 10 (25th pct. 7; 75th pct. 14)), higher oral antidiabetics use, higher 
antihypertensive use. Compared to patients with normonatremia, hyponatremic 
patients had longer LoS (12.10 vs. 8.27 days, p < .001), greater CoS (55.18 vs. 
43.69 thousand DKK, p < .001) and convalescence costs (930 vs. 700 DKK, p <. 
001). Fewer GP visits and lower total GP expenses were observed in the ”post” 
period for hyponatremic patients compared to normonatremic (Table 19). A 
significant relationship was discovered between increasing nadir sodium during 
admissions and both LoS and CoS, both crude and after adjustments. In adjusted 
models, total LoS decreased .49 day per 1 mmol/L increase in nadir sodium, while 
total CoS decreased 1,857 DKKs per 1 mmol/L increase in nadir sodium (Table 20). 
30-day readmission occurred in 22.2% of hyponatremic cases. For the patient group 
as a whole, no significant association was found between nadir sodium value and 
readmission risk (Table 21). For specific diagnoses, lower readmission risk was 
found for ”Unspecified atrial fibrillation and atrial flutter, I48.9”, ”Heart failure, 
unspecified, I50.9”, ”Acute respiratory failure, J96.0”, while the risk was higher for 
”Pneumonia, unspecified organism, J18.9” (Table 4) (Table 21).
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620 (67.5%) 1,086 (68.2%) 2,408 (73%)
** **
Admission 
Number (No) 1 (1;2) 1 (1;2) 1 (1;2)
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136.2 ±3.1 141.6 ±2.4 N/A **
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Charlson Comorbidity Age-Adjusted Index at the Time of Admission
Charlson 
Total Sum




***: p < .001, **: p < .01, * < .05
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Table 20: The Association Between Increasing Nadir P-Sodium (mmol/L), Length 
of Stay (LOS) and Cost of Stay (COS)
Length of Stay 
(Days) per 1 
mmol/L increase in 
P-Sodium
Adjusted Slope
Cost of Stay 
(DKKs) per 1 




Nadir P-Sodium (n=2,512) -.49*** -1,857***
Individual Diagnosis Codes
Sepsis, unspecified organism 
(A41.9,n=26) N/A N/A
Erysipelas (A46.9,n=84) -1.03*** -92
Malignant neoplasm of breast of 
unspecified site (C509,n=14)
N/A N/A
Volume depletion, unspecified 
(E86.9,n=23)
N/A N/A





Alcohol dependence (F10.2,n=170) -.42 -6,240
Multiple sclerosis (G35.9,n=232) N/A N/A
Epilepsy and recurrent seizures 
(G40.9,n=243) -1.33 -1,595
Angina pectoris, unspecified 
(I20.9,n=828) -.66 -2,531
Non-ST elevation (NSTEMI) 
myocardial infarction (I21.4,n=161) -.16 -17
ST elevation (STEMI) and non-ST 
elevation (NSTEMI) myocardial 
infarction (I21.9,n=139)
N/A N/A
Chronic ischemic heart disease, 
unspecified (I25.9,n=464) -.39 -6,076
Pulmonary embolism without acute 
cor pulmonale (I26.9,n=102) -1.71 828
Nonrheumatic aortic valve 
disorders (I35.0,n=285) -.89 -14,024
Unspecified atrial fibrillation and 
atrial flutter (I48.9,n=2,380) -.56** -3,969**
Left ventricular failure (I50.1,n=70)
80
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Heart failure, unspecified 
(I50.9,n=549) -.65 -3,087
Cerebral infarction, unspecified 
(I63.9,n=700) .30 -3,854
Stroke (I64.9,n=202) -.40 3,268
Atherosclerosis of native arteries of 
the extremities (I70.2,n=103) N/A N/A
Phlebitis and thrombophlebitis of 
lower extremities, unspecified 
(I80.3,n=110)
.69 1,505
Unspecified bacterial pneumonia 
(J15.9,n=152) -.69 1,360*
Pneumonia, unspecified organism 
(J18.9,n=1,355) -.80*** -1,349
Chronic obstructive pulmonary 
disease with acute lower respiratory 
infection (J44.0,n=202)
-.39 179
Chronic obstructive pulmonary 
disease with (acute) exacerbation 
(J44.1,n=1,836)
-.12 -1,421




Other and unspecified asthma 
(J45.9,n=184) -.67 -902
Acute respiratory failure 
(J96.0,n=94) -2.73* -8,817
Respiratory failure, unspecified 
(J96.9,n=630) -.60 -575
Crohn's disease, unspecified 
(K50.9,n=124) -.25 -3,395
Alcoholic cirrhosis of liver 
(K70.3,n=122) -.95 875
Calculus of gallbladder without 
cholecystitis (K80.2,n=166) -.42 268
Acute pancreatitis, unspecified 
(K85.9,n=93) .83 -19
Rheumatoid arthritis with 
rheumatoid factor, unspecified 
(M05.9,n=712)
-1.04* -1,546




Unilateral primary osteoarthritis of 
hip (M16.1,n=217) .05 -326
Bilateral primary osteoarthritis of 
knee (M17.0,n=178) .25 -463
Unilateral primary osteoarthritis of 
knee (M17.1,n=276) -.50 -1,917
Chronic kidney disease, unspecified 
(N18.9,n=34) -.46 -5,537
Calculus of kidney (N20.0,n=15) -.30*** 2,594
Acute cystitis (N30.0,n=51) -.55 -36
Cystitis, unspecified (N30.9,n=10) -8.77 -15,910***
Urinary tract infection, site not 
specified (N39.0,n=57) -.38 -309
Fracture of lumbar vertebra 
(S32.0,n=21) -.52 3,646
Fracture of upper end of humerus 
(S422,n=32) -.29 583
Fracture of lower end of radius 
(S525,n=19) .46 2,347




Subtrochanteric fracture of femur 
(S72.2,n=9) -.12 -1,415
***: p < .001, **: p < .01, * < .05
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Table 21: Risk of Readmission According to P-Natrium
Odds Ratio, Readmission 
Within 30 Days
Adjusted
P-Na, Nadir (mmol/L) .986 [.964;1.007]
P-Na, Closest to Admission (mmol/L) 1.014 [.988;1.040]
Sodium Corrected Before Discharge (True/False) 1.002 [.738;1.344]
Diagnosis (Nadir Sodium)
Sepsis, unspecified organism (A41.9,n=26) N/A
Erysipelas (A46.9,n=84) .86 [.63;1.09]
Malignant neoplasm of breast of unspecified site 
(C50.9,n=14) N/A
Anemia, unspecified (D64.9,n=27) .95 [.40;1.88]
Volume depletion, unspecified (E86.9,n=23) N/A
Unspecified dementia (F03.9,n=5) N/A
Alcohol dependence (F10.2,n=22) N/A
Multiple sclerosis (G35.9,n=7) N/A
Epilepsy, unspecified (G40.9,n=9) N/A
Angina pectoris, unspecified (I20.9,n=42) .76 [.52;.98]
Non-ST elevation (NSTEMI) myocardial 
infarction (I21.4,n=22) 1.71 [1.05;6.96]
ST elevation (STEMI) and non-ST elevation 
(NSTEMI) myocardial infarction (I21.9,n=9) N/A
Chronic ischemic heart disease, unspecified 
(I25.9,n=49) .99 [.85;1.16]
Pulmonary embolism without acute cor pulmonale 
(I26.9,n=14) .96 [.53;1.79]
Nonrheumatic aortic (valve) stenosis (I35.0,n=15) N/A
Unspecified atrial fibrillation and atrial flutter 
(I48.9,n=226) .91 [.83;1.00] *
Heart failure, unspecified (I50.9,n=41) .81 [.63;.97] *
Stroke (I64.9,n=20) .94 [.40;1.91]
Atherosclerosis of native arteries of the extremities 
(I70.2,n=8)
N/A
Phlebitis and thrombophlebitis of lower 
extremities, unspecified (I80.3,n=13)
N/A
Unspecified bacterial pneumonia (J15.9,n=13) N/A
Pneumonia, unspecified organism (J18.9,n=213) 1.09 [1.00;1.18] *
Chronic obstructive pulmonary disease with acute 
lower respiratory infection (J44.0,n=44) 1.17 [.90;1.60]
Chronic obstructive pulmonary disease with 
(acute) exacerbation (J44.1,n=308) 1.06 [.99;1.15]
83
83
Chronic obstructive pulmonary disease, 
unspecified (J44.9,n=302) 1.00 [.94;1.07]
Other and unspecified asthma (J45.9,n=18) N/A
Acute respiratory failure (J96.0,n=28) .68 [.43;.92] *
Respiratory failure, unspecified (J96.9,n=36) N/A
Crohn's disease, unspecified (K50.9,n=13) N/A
Alcoholic cirrhosis of liver (K70.3,n=16) 1.49 [.95;3.85]
Calculus of gallbladder without cholecystitis 
(K80.2,n=15)
N/A
Acute pancreatitis, unspecified (K85.9,n=20) N/A
Rheumatoid arthritis with rheumatoid factor, 
unspecified (M05.9,n=74) 1.01 [.76;1.39]
Rheumatoid arthritis, unspecified (M06.9,n=62) .91 [.76;1.08]
Unilateral primary osteoarthritis of hip 
(M16.1,n=26)
N/A
Unilateral primary osteoarthritis of knee 
(M17.1,n=32)
N/A
Osteoarthritis of first carpometacarpal joint, 
unspecified (N18.9,n=34) .81 [.51;1.14]
Calculus of kidney (N20.0,n=15) N/A
Acute cystitis (N30.0,n=51) 1.00 [.84;1.22]
Urinary tract infection, site not specified 
(N39.0,n=57) 1.28 [.97;1.89]
Benign neoplasm of cerebral meninges 
(S32.0,n=21) N/A
Fracture of upper end of humerus (S42.2,n=32) .79 [.47;1.16]
Fracture of lower end of radius (S52.5,n=19) N/A
Fracture of head and neck of femur (S72.0,n=172) 1.08 [.96;1.25]
Pertrochanteric fracture (S72.1,n=86) .86 [.66;1.10]
***: p < .001, **: p < .01, * < .05
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3.7 - PAPER 7
Kruse C, Eiken P, Vestergaard P. 
Thiazide diuretics, bone mineral density and electrolytes: a systematic review and 
meta-analysis. Submitted 2017 July to Journal of Hypertension
3.7.1 - MATERIALS AND METHODS
The study was a systematic review and meta-analysis of randomized controlled 
trials examining thiazide use on BMD and electrolyte concentrations in serum and 
urine samples.
3.7.1.1 - SYSTEMATIC REVIEW
3.7.1.1.1 - LITERATURE STUDY
A systematic review was performed in February 2017 regarding thiazide use, bone 
mineral density progression (DXA-based) and changes in serum and urine samples 
of specific bone-related analyses. PRISMA guidelines were followed. The scope of 
the literature search comprised the Cochrane Library, EmBASE, PubMed, 
SCOPUS, Web of Science and SveMed+. For exposure keywords, general 
compound terms for thiazides and specific chemical forms were used. For outcome 
terms, bone mineral-related keywords, DXA-related keywords, osteoporosis-related 
keywords and the specific electrolytes were included.
3.7.1.1.2 - STUDY INCLUSION AND EXCLUSION
Studies were included for further analysis based on the following inclusion criteria; 
1) randomized controlled trial design, 2) adult study participants, 3) female or mixed 
study population, 4) thiazide diuretics as solitary agent or combined with 
antiresorptives, 5) thiazide diuretics not compared to other diuretic agent, 6) study 
duration of minimum 6 months. Studies were similarly excluded if the following 
criteria were met: 1) not a randomized controlled trial and/or no control group, 2) 
publications that were conference abstracts, review articles or letters to the editor, 3) 
if included patients suffered from osteoporosis, this could not of a secondary nature, 
e.g. rheumatoid arthritis, malignancy-induced, gastroenterology disease.
3.7.1.1.3 - STUDY ASSESSMENT
Meta-data from all abstracts of all database sources were extracted and combined to 
one common format with the following information; 1) sequential ID number, 2) 
database source, 3) year, 4), journal, 5) authors, 6) title and 7) full abstract text. An 
interactive system was constructed in the R Statistical Software Package to present 
one abstract text and title at a time with blinding of journal, authors and year. Two 
of the authors, CK and PV, each assessed all abstracts as either “Accepted” or 
“Rejected”, the latter with associated reasons for decline. Decisions were stored to 
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allow for Kappa agreement calculations. Missing abstract texts were manually 
sought after by internet searches. Disagreements between reviewers were discussed 
internally and final decisions were made. From the accepted abstracts, full-texts 
were gathered either from online or Danish national library sources. All full-texts 
were assessed by CK and accepted or rejected according to outlined criteria for 
inclusion and exclusion.
3.7.1.1.4 - DATA EXTRACTION
From the final full-texts, the following data were extracted: 1) first author name, 2) 
title, 3) publication year, 4) journal name and abbreviation, 5) patient age (mean or 
median where applicable), 6) number of participants in either intervention or control 
group, 7) intervention and control group agent, name of pharmacologic agent and 
role as solitary or additive agent. Baseline and follow-up mean and standard 
deviations of the aforementioned end-points were calculated.
3.7.1.1.5 - BIAS ASSESSMENT
The included studies were assessed using the Cochrane Risk of Bias215 tool to 
evaluate bias in reporting, detection, bias and selection. We used three groups of 
risk; low risk, moderate risk, high risk, and a separate category if “not applicable”.
3.7.2 - STATISTICAL ANALYSIS
For each outcome, at least 2 studies were required for completion. Both fixed and 
random effects models were applied for each outcome, with study heterogeneity 
then deciding if the fixed or random effects model effect sizes were presented. 
Continuous outcomes were presented with standardized mean differenced and 95% 
CI. A p-value of < .05 was considered statistically significant. I2 above .50 (50%) 
and a Q statistical significance level below 5% were used to assess and conclude 
study heterogeneity. 
Publication bias was assessed by funnel plots and linear regression tests of plot 
asymmetry.
3.7.3 - SUMMARY OF RESULTS
2,780 abstracts including duplicates were found using the search strategy. Reviewer 
#1 (CK) accepted 41 abstracts while reviewer #2 (PV) accepted 35 abstracts. 29 
abstracts were assessed as not complete and gathered from external sources. In the 
final comparison, 25 abstracts were agreed upon, while 10 abstracts were disagreed 
upon (Unweighted Kappa agreement 83% [73% ; 93%]). The individual 
disagreements were discussed and 34 abstracts were selected for full-text inclusion. 
Seven (n=7) studies were included in the quantitative synthesis. 
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3.7.3.1 - BONE MINERAL DENSITY
The fixed effects model showed a non-significant, albeit borderline positive effect 
on BMD among thiazide users compared to control groups (Figure 4, SMD 0.0854 
[-0.005 ; 0.175], p = .063). Heterogeneity was not present (I2 = 0.0%, Q = .95 (p = 
1.00)). Test for between-subgroup differences was insignificant (Q = .50, p = .99) in 
the fixed effects model (Q = .50, p = .99). The contour funnel plot did not indicate 
publication bias (Figure 5).
Figure 4: Forest plot of BMD meta-analysis
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Figure 5: Contour funnel plot, BMD outcome
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3.7.3.2 - SERUM CALCIUM
The random effects model showed a significantly increased Se-Ca among thiazide 
users compared to control groups (Figure 8, SMD .44 [.08 ; .81], p < .05). 
Significant study heterogeneity was discovered (I2 = 66.0%, Q = 11.85 (p < .05). A 
contour funnel plot (Figure 9) was symmetrical and agreed on a positive, significant 
effect. A linear regression model of funnel plot asymmetry did not indicate 
significant asymmetry (t = 1.98, p = .14).






























3.7.3.3 - SERUM PHOSPHATE
The random effects model did not show significant changes in serum phosphate 
among thiazide users compared to control groups (Figure 10, SMD -.41 [-1.05 ; 
.23], p = .21). Significant study heterogeneity was discovered (I2 = 84.0%, Q = 
18.22 (p < .05). ). A contour funnel plot did not indicate small-study bias (Figure 
11). A linear regression model of funnel plot asymmetry did not indicate significant 
asymmetry (t = -.74, p = .53).
Figure 10: Forest plot, serum phosphate outcome
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Figure 11: Contour funnel plot, serum phosphate outcome
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3.7.3.4 - PARATHYROID HORMONE
The random effects model showed a borderline significant lower PTH among 
thiazide users compared to control groups (Figure 12, SMD -.42 [-.95 ; .11], p = 
.12). Significant study heterogeneity was discovered (I2 = 70.0%, Q = 6.68 (p < 
.05). A contour funnel plot did not indicate small-study bias (Figure 13). A linear 
regression model of funnel plot asymmetry did not indicate significant asymmetry (t 
= -.83, p = .56).
Figure 12: Forest plot, parathyroid hormone outcome
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Figure 13: Contour funnel plot, parathyroid hormone outcome
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3.7.3.5 - ALKALINE PHOSPHATASE
The fixed effects model did not show significant changes in ALP among thiazide 
users compared to control groups (Figure 14, SMD .08 [-.31 ; -.48], p = .68). No 
study heterogeneity was discovered (I2 = 0.0%, Q = 0.06 (p = 0.80). A contour 
funnel plot did not indicate small-study bias (Figure 15). A linear regression model 
of funnel plot asymmetry could not be completed.
Figure 14: Forest plot, alkaline phosphatase outcome
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Figure 15: Contour funnel plot, alkaline phosphatase outcome
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3.7.3.6 - URINARY CALCIUM
The random effects model showed a significantly lower U-Ca among thiazide users 
compared to controls (Figure 6, SMD -.96 [-1.72 ; -.20], p < .05). Significant study 
heterogeneity was discovered (I2 = 90.0%, Q = 30.1 (p < .05). The contour funnel 
plot indicated publication bias in the sense that positive effects were more likely to 
be published (Figure 7). A linear regression model of funnel plot asymmetry could 
not be completed.
Figure 6: Forest plot; urinary calcium outcome 
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Figure 7: Contour funnel plot, urinary calcium outcome
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3.7.3.7 - BIAS ASSESSMENT
Generally, a low risk of bias was found in all aspects of selection, blinding and 
outcome data collection. In certain studies, with no apparent pattern of year of 
publication, not all visit measurements were made available and there was a greater 
focus on visualizing progression of measurements compared to table presentations. 
No other obvious sources of bias were discovered (Figure 16).




















































































































































































































3.7.3.8 - SENSITIVITY ANALYSIS 
For the outcome “serum calcium”, all study combinations without the study of 
Scholz et al216 resulted in lower I2 while maintaining a significantly positive effect 
size for the random effects model (Figure 17). For the outcome “serum phosphate”, 
exclusion of the Scholz et al216 study decreased both the study I2 and effect size of 
the random effects model to non-significance (Figure 18). For the outcome “urinary 
calcium”, study heterogeneity remained for all study combinations (Figure 19).
Figure 17: Sensitivity Analysis for the Serum Calcium outcome
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Figure 18: Sensitivity Analysis for the Serum Phosphate outcome
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4.1 - PAPERS 1-4, 6 (REGIONAL AND NATIONAL DANISH DATA): 
Five of the included papers in this thesis are based on patient registry data collected 
on a regional level at Aalborg and Aarhus University Hospitals, combined with 
national data from the National Danish Patient Registry spanning several million 
individuals. There are both strengths and weaknesses to utilizing data resources of 
such a magnitude. The data reflects a prospective, real-life clinical setting and 
therefore reveals behavioral patterns that would be observed on a population-level 
outside a controlled research setting. Treatment adherence and effects related to age 
and temporal changes can illustrate use of certain pharmaceuticals and risk factors 
outside a controlled clinical setting. The large sample size also allows for sub-group 
analyses without limiting statistical power by selection. 
However, data will be analyzed retrospectively and considerations about the scope 
and control of data collected are needed. For the DXA and biochemical data used in 
these papers, the population sample consisted of patients who had been referred to a 
DXA scan by their GP, not as a general research sample from the entirety of the 
originating population. This results in an inherent risk of selection bias, as patients 
who are more health-oriented, are within certain age groups and/or have risk factors 
for osteoporosis will more likely be referred than the general population. Severe 
cases of non-manifest osteoporosis due to poor health awareness, poor 
socioeconomic conditions or GP adherence could decrease the likelihood of being 
referred to a DXA scan. The same arguments can be placed on the blood samples, as 
data were collected based on blood samples in a normal clinical routine setting, not 
a research setting. 
Specifically, for paper 1, when investigating the relationship between serum sodium, 
BMC and BMD, it is likely that patients with a serum sodium measurement 
available had this procedure performed due to greater health awareness or specific 
comorbidity compared to patients without serum sodium measurements. As 
hyponatremia was associated with parameters of greater frailty, i.e. older age and 
lower weight, it can be speculated that a population group with more severe 
hyponatremia and/or osteoporosis is not represented fully in the available data. 
Further in paper 2, the exclusion of patients with infrequent samples (assessed by 
calendar quarters with sodium samples) also contains a risk of selection bias, as 
patients with readily available sodium samples are likely more health oriented and 
well-adherent compared to those with less frequent samples. For both studies, the 
study period of data collection was long, which would normally cause concern about 
temporal changes in sample collection and analyses. However, low drift over time 
was observed for the DXA scan data and a daily QC program was in place for both 
sites, limiting the risk of compromised data quality.
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Papers 3 and 4 do not utilize DXA or biochemical data and reflect how data in the 
national Danish patient registry are collected automatically and prospectively. The 
risk of information bias from the patients is therefore limited, but due to the 
retrospective nature of analyzing the data, certain sources of bias can be introduced. 
The reconstruction algorithm was not ascertained for the entirety or parts of the 
sample, and an estimate of adherence, e.g. percentage consumed of reimbursed doe, 
cannot be provided. Prolongation by 20% could be insufficient in some cases where 
large doses are reimbursed, e.g. as C03AB exists in 250 tablet sizes. Overlaps did 
not account for expiration dates of the medicine or repurchases, so the assumption 
that patients were fully adherent for several years cannot be ascertained easily.
4.2 - PAPER 5 (REGIONAL BELGIAN DATA):
This paper uses data collected prospectively over several years and investigates 
them at a cross-sectional level to predict future events. Several precautions were 
made to ensure high data quality. Patients had blood samples drawn in a fasting 
condition by trained laboratory technicians with certified Belgian credentials. DXA 
scanners were subjected to a daily QC program to ensure low drift over time. CVs 
were not available. Questionnaires were validated and internationally used tools. 
Blood pressure devices, stopwatches and dynamometers were calibrated. Grip 
strength, balance test and TGUG were performed several times to allow for mean 
and maximum value calculations.
The main methodological concern of this paper relates to the sample size and the 
prediction error intervals resulting from this approach. For the mortality outcome, 
the data quality of both the visit date and the ascertainment of mortality can be 
regarded as high, yet the exclusion of participants who participated in 1996 and not 
in 1997 resulted in only a moderate sample size being available when the data was 
split into training and test datasets. By further choosing an allocation of 75% to the 
training dataset and 25% to the test dataset, this infers a trade-off between higher 
predictive capability and subgroup pattern recognition with more training data, but 
greater test error when applying the model to new and unseen data. 
Greater sample sizes than those available could have increased predictive capability. 
Thereby, a higher AUC would lend greater strength to the relative predictor 
importance. Probability calibration is also too difficult to perform credibly with a 
low sample size, as very small probability bins of events will occur if the entire 
spectrum of probabilities is not represented. A similar concern is the stability of the 
model predictions and predictor importance with increasing sample sizes. Models 
such as the “random forest” and “multivariate adaptive regression spline” are 
considered stable in terms of predictive power.
4.3 - PAPER 7 (SYSTEMATIC REVIEW AND META-ANALYSIS):
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The main methodological concern of performing the meta-analysis in paper 7 relates 
to data extraction, as precautions were made to ensure a reproducible and agreed-
upon study selection and sensitivity analysis procedure. Data were extracted from 
the published versions of the included papers which did not all present data 
transparently by means, SD or equivalent, transformable parametric data. For some 
studies, only graphical presentations of the results could be used to extract data on 
the specific end-points and time periods that were studied. The transformation from 
standard error or confidence interval to mean and SD is not as accurate as extracting 
parameters directly from datasets.
Further consideration relates to the age of certain papers. For certain end-points, i.e. 
serum phosphate, relatively few studies were included and a substantial proportion 
among them were older studies, possibly with different temporal effects and 
treatment standards. The strengths of the study were the novel, iterative sensitivity 
analysis to study the effects of heterogeneity when excluding specific study. This 
adds weight to the perception that the findings can be reproduced in new studies, as 
the excluded study consisted of a patient group with certain added characteristics, 
i.e. nephrolithiasis in the Scholz et al. study216. The literature study was performed 
with exhaustive combinations of search terms related to the outcomes, which led to 
a large number of abstracts needed screening, but also limited the risk that relevant 
studies were excluded. Using an interactive selection procedure limited risk of false 
exclusions and allowed for calculations of agreements between the two observers. 
4.4 - DATA SOURCE QUALITY
4.4.1 - DXA SCAN DATA
The DXA scan data used for papers 1 and 2 were collected in a clinical setting by 
trained laboratory staff. Scans were performed using Hologic™ machines (Hologic 
1000, Hologic 2000, Hologic Discovery) that all underwent a QC program of 
phantom scans and cross-calibration with low drift over time. The precision errors 
were very low; columna LSC 2.49%, total hip 2.78% and femoral neck 4.96%.
4.4.2 - BIOCHEMISTRY DATA
The biochemistry data originated from two departments of biochemistry at Aalborg 
and Aarhus University Hospitals in Denmark. Both institutions were certified by 
national agencies, i.e. DANAK for both the Department of Biochemistry at Aalborg 
University Hospitals (Appendix 9) and the Department of Biochemistry and 
Microbiology at Aarhus University Hospitals (Appendix 11). For the serum sodium 
samples used in papers 1 and 2, the sample was analyzed on a Roche-Cobas 6000/ 
8000 with measureable interval between 80 and 180 mmol/L. At the low and high 
ends of the reference interval, the precision error was 2 SD (Appendix 10).
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4.4.3 - DANISH PATIENT REGISTRY DATA VALIDITY
Data originating from the National Danish Patient Registry are collected 
prospectively and automatically, and is governed by national institutions to ascertain 
collection procedures are followed. Logical rules are applied to data to limit 
inconsistencies. The validity of diagnoses codes used in the National Danish Patient 
Registry has been studied with different scrutiny depending on specialties and 
disease categories. 
For fractures specifically, few studies exist that all present favorable metrics on hip 
fracture validity. In a validity study of female Danish nurses217, the positive 
predictive value was estimated at 89% for hip fractures, 75% for wrist fractures and 
54% for upper arm fractures. In an older study, the precision of fracture diagnosis 
has further been estimated at 82%218, while for certain patient groups, the validity is 
estimated to exceed 97%219. 
For other diagnoses, particularly the outcome diagnoses examined in paper 6, there 
is a generally high degree of validity in the National Danish Patient Registry220. 
Diagnoses within cardiology have a high degree of validity for general diagnoses of 





5.1 - SUMMARY OF RESULTS
 Hyponatremia was associated with lower BMC and BMD and a higher risk 
of osteoporosis in all regions of interest in DXA-scanned hips compared to 
normonatremic patients.
 No association was found between hyponatremia, decreasing serum sodium 
and BMC or BMD in the lumbar spine DXA-scanned regions of interest, 
nor with a higher risk of WHO-defined osteoporosis in the lumbar spine 
alone.
 Chronic mild hyponatremia ([Na+] = 130-137 mmol/L) was associated 
with lower BMC and BMD at baseline and with worse progression of BMC 
and BMD in several regions of interest in the hip. In the lumbar spine, only 
sporadically was chronic mild hyponatremia associated with worse 
progression of BMC and BMD.
 Thiazide users have an increased weekly risk of fracture prior to 
commencing therapy, which shows trends towards further increases during 
weeks 0-42 after commencing therapy. From weeks 43, continued use was 
associated with a linear trend towards decreasing per-week risk of fracture.
 From the age of 73, commencing therapy with thiazide diuretics is 
associated with an increased 10-year risk of fracture compared to non-
users. Between 50 and 73 years of age, the risk is comparable to non-users.
 Previous randomized controlled trials show a borderline positive effect of 
thiazide use on BMD.
 Thiazide use causes lower urinary calcium, higher serum calcium, lower 
serum phosphate and borderline significantly lower plasma parathyroid 
hormone, but no change in serum alkaline phosphatase.
 Neither serum sodium nor thiazide use are relatively good predictors of 
mortality for older men compared to markers of physical performance.
 Hyponatremia during hospital admissions is associated with longer lengths 
of stay and greater costs of stay compared to normonatremic patients.
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5.2 - BONE MINERAL CONTENT IN HYPONATREMIA
The primary hypothesis of this thesis was that hyponatremia is associated with 
lower BMD and a higher risk of osteoporosis compared to normonatremia. This 
hypothesis is based on previous epidemiologic studies of European and North 
American patients18,116,120,224 as well as basal in vitro studies examining the effect of 
hyponatremia on osteoblast and osteoclast stem cells20,122. 
“Paper 1” reaffirmed this association using a large Danish patient sample and adds 
substantial knowledge about medication use and comorbidity presence. 
Hyponatremia was found to be associated with lower BMC and BMD in all DXA-
scanned regions of interest in the hip, with no association to osteoporosis in the 
lumbar spine. A novel finding was the difference between the hip and the lumbar 
spine in terms of severity, as lower sodium was linearly associated with lower BMC 
and BMD in all regions of the hip, while the same linear association was not shown 
between decreasing serum sodium and BMC or BMD in the lumbar spine’s regions 
of interest. A possible explanation for this discrepancy is the difference in bone 
composition in the hip versus the lumbar spine. While the lumbar spine is composed 
mainly of trabecular bone to absorb gravitational energy and provide an elastic 
response hereto, the hip is composed mainly of cortical bone225–229. These 
differences are thought to arise from evolutionary needs of hip mobility versus 
shock absorption in the lumbar spine. The discovery in “paper 1” that regions of 
cortical bone seem to be more affected by hyponatremia is an original discovery and 
gives rise to a new hypothesis that aligns with older studies of sodium content in 
different areas of bone230–232. In canine studies as well as older isotope studies, it has 
been documented that cortical bone contains a relative abundance of sodium. A 
possible cause of hyponatremia-induced loss of bone mineral content is that the 
organism senses lower serum concentrations of sodium and mobilizes sodium from 
these bodily stores by osteoclast activity231,232. 
This hypothesis is supported by the previous in vitro findings of Verbalis et al. and 
Barsony et al.18,20 where dilutional hyponatremia increased osteoclast activity and 
resorptive capability, even when the group adjusted for the resulting hypoosmolality 
of hyponatremia by insoluble mannitol. This technique strengthens the argument 
that the increased bone resorption observed in hyponatremia could be caused 
specifically by activation of sodium receptors and not by osmosensing receptors. 
One caution, however, is the conflicting role of vasopressin in bone and water 
metabolism. As noted previously, some studies have rejected that vasopressin 
activates and recruits osteoclasts126, while others have shown an association between 
vasopressin and osteoporosis123,124. A very recent study by Greiller et al. showed 
further evidence that SIADH and the related abundance of vasopressin induces 
hypercalciuria which could aggravate bone resorption233. Further investigations of 
vasopressin are warranted, e.g. by stimulating cell culture responses of direct 
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vasopressin exposure when adjusting for hyponatremia and hypoosmolality through 
added sodium and mannitol.
An additional problematic aspect in the causal pattern of hyponatremia and lower 
bone mineral content are the phenotypes associated with hyponatremia and 
osteoporosis, and the resulting confounding that affects the overall understanding of 
the connection between the two. As it was documented in “paper 1”, patients with 
hyponatremia were older, weighted less and therefore had lower BMI. In 
hyponatremic patients, greater use of specific medication types known to cause 
hyponatremia or increased bone resorption, i.e. benzodiazepines, opioids and 
antihypertensives, were also found. In “paper 1”, adjustments were made for 
aggravating factors; age, gender and BMI, but inclusion of more factors would 
necessitate a larger sample size than 1,600 to allow for multiple comparison 
adjustments and to limit statistical type 1 and type 2 errors.
5.3 - PRO-RESORPTIVE MECHANISMS OF HYPONATREMIA
A secondary hypothesis of this study was that chronic hyponatremia exacerbates 
osteoporosis progression compared to normonatremia. This hypothesis was based on 
previous cellular works that investigated the responses of hyponatremia on 
mesenchymal and macrophage stem cells, and how this affected resorptive 
capabilities when exposed to bone tissue18,20,122. 
In “paper 2”, evidence was found that chronic hyponatremia is associated with 
worse progression of osteoporosis compared to normonatremic subjects. 
An association was found between chronic mild hyponatremia ([Na+] 130-137 
mmol/L) and greater loss of trochanteric, femoral neck and absolute total hip BMD, 
and with greater loss of L1, L3 and L4 BMC. These findings were not as universal 
for one region as the association between lower serum sodium and lower BMD in 
all regions of the hip in “paper 1”, but patients with chronic mild hyponatremia did 
also start their periods of observation at a worse offset of lower hip BMC and BMD 
compared to normonatremic subjects. 
Hyponatremic subjects began with lower BMD and suffered greater losses despite 
this fact. This gives rise to two hypotheses about this temporal effect. One is that 
hyponatremic patients are referred inappropriately late to their first DXA scan, at 
which it becomes relatively more difficult to sustain BMD and prevent fracture 
occurrence and progressive BMD loss. Evidence of this is the high mean age of 
67.36 years (Table 6) at which hyponatremic patients underwent their first DXA 
scan, as well as the lower GP use observed in “paper 6” when hyponatremic patients 
are discharged. The age of 67 is above the ICSD recommendations that post-
menopausal women should be referred to BMD estimation between ages 50-65 if 
one or more risk factors for low BMD are present. A further hypothesis is that 
hyponatremia is a risk factor that warrants a lower age cut-off. The second 
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hypothesis that “paper 2” gives rise to is the worrying aspect that adjustments for 
oral antiresorptives did not limit the increased bone loss caused by mild 
hyponatremia. If this finding is affirmed in prospective study, it would mean that the 
pro-resorptive mechanisms of hyponatremia-induced osteoporosis overwhelms the 
inhibition of mature osteoclasts by bisphosphonates, and possibly necessitates more 
aggressive therapy at the level of the RANK ligand immunoglobulin, denosumab234. 
This hypothesis is supported by the in vitro studies of Verbalis et al.18 and Barsony 
et al.20 where a dose-response relationship was found between lower sodium 
concentrations and both larger and more active (assessed via TARP-positive 
multinucleated cells235,236) osteoclasts, as well as more resorptive power assessed by 
resorption of dentin20. 
In future studies, an attempt to confirm this association should made by a cross-
sectional study of human biomarker levels of bone resorption, i.e. CTX237, with 
decreasing levels of serum sodium. From the perspective of the second major type 
of bone-related cell, the osteoblast, the finding from Fibbi et al.122 of increased 
adipocyte differentiation with hyponatremia warrants further study and affirmation 
to understanding in this causal mechanism. While this hinders the presence of 
osteoblast and therefore a bone-forming response in regular physiology, this could 
also cause deteriorating bone quality as measurements of BMC or BMD in a DXA 
scan become unreliable with increased presence of fatty tissue. Secondly, mild 
hyponatremia ([Na+] 130-137 mmol) is generally considered a benign finding not 
associated with increased bodily distress necessitating diagnostic workup or 
therapeutic intervention119,238,239. If hyponatremia-induced osteoporosis commences 
at this mild level of hyponatremia, it warrants a new and more aggressive approach 
to hyponatremia management among this patient group.
5.4 - FRACTURE PROTECTION WITH THIAZIDE USE
The second primary hypothesis and a major aim of this thesis was to investigate 
potential age groups that benefit more from thiazide use than others. As substantial 
work has already been done to investigate a protective effect of thiazides on fracture 
risk, both through prospective and retrospective studies, the studies in “paper 3” and 
“paper 4” were designed not to reaffirm these associations, but to use the substantial 
sample size and automatic nature of data collection available from Danish registries 
to investigate temporal and age-related effects of this association. In “paper 4” of 
10-year fracture risk of thiazide use, systematic age-groups of decreased fracture 
risk were not found, but strong signals of increased fracture risk, i.e. where not to 
commence and when to discontinue therapy, were found. 
Commencing therapy between ages 50-63 was associated with a comparable 10-
year risk; commencing therapy after age 73 was associated with increased 10-year 
fracture risk, and discontinuing therapy after age 63 was associated with lower 10-
year fracture risk. These findings should be regarded in light of the physiological 
changes that occur in females after menopause and with further increases in age. It 
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has been shown in several studies that estrogen-depletion in menopause affects 
calcium homeostasis by increasing urinary excretion of calcium, and that 
supplementation of estrogen reduces this effect240–243. Lower calcium reabsorption 
causes a relatively lower abundance of mineralization components in serum and 
increases the need to mobilize calcium from bone and gastrointestinal absorption via 
increased PTH production244,245. The years between onset of menopause and age 65 
are the ones of accelerating bone resorption until a progressively linear slope is 
observed246. 
The latest (2015) ISCD Official Positions247 recommend that BMD be assessed for 
women above the age of 65 or post-menopausal women younger than 65 with one of 
more risk factors for low bone mass:
 Low body weight
 Prior fracture
 High risk medication use
 Disease or condition associated with bone loss.
Women during the menopausal transition are recommended to be referred if one or 
more clinical risk factors for fracture, i.e. low body weight, prior fracture or high-
risk medication use, are present. If osteoporosis is diagnosed, treatment with oral 
antiresorptives, calcium and vitamin D is warranted1. 
From the findings of “paper 4”, a new hypothesis can be made that thiazide-induced 
fracture protection occurs due to increased renal reabsorption of calcium and lower 
resorptive inclination by borderline lower PTH. This would explain the age-specific 
risk patterns between 50-63 where the risk was found to be comparable. A 
speculative explanation is that the calcium-retention effect provides the greatest 
degree of protection in this age group, while other mechanisms that increase fracture 
risk become relatively more predominant in older age groups, i.e. thiazide-induced 
hyponatremia. If this is true, it provides an explanation why the risk trends 
exponentially towards higher risk when commencing thiazide therapy after age 73. 
The finding that discontinuing therapy after age 63 is beneficial on 10-year fracture 
risk can be explained with lower hyponatremia risk when not receiving therapy.
If this rationale was to translate into clinical use, it would be one where thiazides are 
prescribed independently based on hypertension or an aim to protect from fractures 
and progression of osteoporosis. In the event that no comorbidities that necessitate 
thiazide use are present, e.g. hypertension, edema or calciuretic disease, thiazides 
would be prescribed at the onset of menopause and continued until other clinical 
recommendations of DXA scans come into effect at a higher age. In terms of 
duration of therapy, “paper 3” supports an approach where thiazides are used 
continuously and uninterrupted for several years, as the protective effects are likely 
to occur after 43 weeks of continuous use.
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5.5 - THIAZIDE USE AND BONE MINERALIZATION
The patterns observed in “paper 3” and “paper 4” are substantiated by the causal 
effects observed in the meta-analysis of clinical trials in “paper 7”. Evidence was 
found that thiazide use causes lower urinary excretion of calcium, increased serum 
calcium, borderline significantly lower PTH, lower serum phosphate, but no 
difference in serum alkaline phosphatase. 
From this pattern, a hypothesis can be formed of how thiazides alter bone 
metabolism:
 Urinary calcium excretion decreases and causes an increase in serum 
calcium
 Increased serum calcium lowers serum PTH via inhibition of the CaSR
 Serum phosphate decreases due to decreased gastrointestinal absorption by 
lower PTH, lower 1,25-dihydroxycholecalciferol and increased urinary 
excretion due to thiazides
o Lower serum phosphate decreases FGF-23 activity57,248 and 
increases maximum availability of active 1,25-
dihydroxycholecalciferol
o Lower PTH and decreased 1,25-dihydroxycholecalciferol 
decreases bone mobilization of calcium249
The pattern of altered electrolyte metabolism simultaneously leads to unanswered 
questions:
 How does lower serum phosphate affect the mineralization quality of bone 
hydroxyapatite?250,251
 Should the unchanged concentration of alkaline phosphatase be seen as a 
marker of non-increased bone resorption?
 What is the relative weight between lower 1,25-dihydroxycholecalciferol 
by lower PTH and greater 1,25-dihydroxycholecalciferol by lower FGF-23 
in a thiazide-exposed patient, particularly in relation to bone resorption?
The findings form a pharmacological argument for the use of thiazides in 
osteoporosis, as the patterns and possible causal chain are beneficial in an 
environment of increased bone resorption such as post-menopausal osteoporosis. 
However, the meta-analysis of the randomized controlled trial was only borderline 
significant in terms of a beneficial role of thiazides directly on bone mineral density 
progression. More statistical power via more clinical trials is needed to ascertain this 
protective pattern. As more than two studies were required for each end-point of the 
meta-analysis, insufficient studies were available to study the direct effects of 
thiazides on biochemical markers of bone resorption and anabolism. A lack of 
newer studies within the field also means that newer markers, e.g. CTX, P1NP252, 
and osteocalcin253–255, have not been studied previously. These are necessary to 
further examine the potential causal change in thiazides’ effect on bone mineral 
density. This will aid our understanding of the mineralization quality and activity 
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caused by thiazides, as these are currently unanswered by the available clinical 
trials.
5.6 - BMD-INDEPENDENT FRACTURE RISK FACTORS
An added matter of complexity is represented by increased fracture risk 
independently of low BMD that seems to occur with hyponatremia. As exemplified 
by the work of Renneboog et al.256, hyponatremia affects postural balance and gait 
stability in a negative way, which is reversible when attaining normonatremia 
through therapy. 
In “paper 5”, the relative role of hyponatremia in predictive models of mortality and 
incident immobility was assessed in data of older European men. While not the 
same patient phenotype as the subjects of “paper 1” and “paper 2”, serum sodium 
and thiazide use did not figure among the most important predictors of either 
mortality or incident immobility. As a prediction model used at a cross-sectional 
level, no conclusions can be made about possible causalities, but the relatively low 
importance of serum sodium when predicting incident immobility indicates that 
other biochemical analyses such as 25-hydroxycholecalciferol and plasma 
testosterone infer greater weight on future physical performance. 
Also in the descriptive comparison between 5-year mortality and 5-year survival, no 
difference in serum sodium was observed between the groups with very high 
statistical confidence, while markers of physical performance were worse in the 
mortality group (i.e. RDRS-2, TGUG, grip strength and SMI). This warrants further 
study of if and how hyponatremia causally affects physical performance, as the 
findings of in vitro studies257 that hyponatremia can affect muscle tissue by collagen 
infiltration does not translate to lower physical performance in vivo in this paper. 
From an ethical standpoint, the effect on physical performance when correcting 
from chronic hyponatremia to normonatremia would be an apt first choice to study 
this inference in more detail.
5.7 - THRESHOLDS FOR HYPONATREMIA INTERVENTION
The findings of hyponatremia’s role in both osteoporosis, mortality and burdens of 
therapeutic care also warrant a discussion about thresholds for intervention and 
diagnostic workup. Currently, mild hyponatremia between 130-137 mmol/L is 
seldom seen as requiring full workup and intervention to correct to normonatremia, 
but a growing body of evidence within the scope of this thesis and other areas, 
particularly mortality238,258,259, are increasingly suggesting a more aggressive 
approach to management of mild hyponatremia. 
From the papers of this thesis, retrospective associations have been found between 
decreasing serum sodium and increased risk of osteoporosis, lower hip BMC and 
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BMD and increased lengths of stay and costs of stay during hospitalizations. Other 
recent epidemiologic studies238,258, have shown strong associations between 
categorically lower sodium concentrations and increased mortality in patients at 
general practitioners. The papers of this thesis do not examine the effect of 
correcting hyponatremia on mortality and BMD progression, and as such, a new 
hypothesis warranting further investigation is whether this protects from mortality 
and fracture occurrence. 
In a retrospective study by the Verbalis group15, chronic hyponatremia with no 
correction further increased fracture risk compared to non-correction. A current 
clinical study in Cologne, the “Characterization of Neuropsychologic and Physical 
Performance in Geriatric Patients With Hyponatremia” study (ClinicalTrials ID: 
NCT02242604), is examining whether patients with serum sodium below 130 
mmol/L are affected positively in terms of physical performance, cognitive ability 
and mortality by correction to normonatremia. 
A further hypothesis that warrants investigation is whether correcting moderate and 
mild hyponatremia either by limiting the causal mechanism and/or altering water 
metabolism through vaptans cause improve bone mineralization through lower 
resorption and improved bone formation.
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5.8 – VISUALIZING THE RELATIONSHIP BETWEEN 
HYPONATREMIA, THIAZIDES AND OSTEOPOROSIS
The intricate relationship between hyponatremia, thiazides and osteoporosis is 
visualized in figure 20 as a combination of state-of-the-art knowledge with the novel 
findings and hypotheses generated from this thesis. The points of contention needed 
to be further clarified are also illustrated. 
5.8.1 – ELECTROLYTE DISTURBANCES
Evidence exists that thiazides increase the risk of several electrolyte disturbances, 
i.e. hyponatremia, hypomagnesemia, hypophosphatemia and hypercalcemia. 
Individually, these four have been shown to decrease PTH secretion and FGF-23 
activity, but further study is warranted to document the relative importance of:
1) Decreased bone resorption by lower PTH secretion itself
2) Decreased calcium mobilization from bone by lower 1,25-
dihydroxycholecalciferol by lower PTH 
3) Greater or lower bone formation by greater 1,25-dihydroxycholecalciferol 
caused by lower FGF-23 activity
Novel hypotheses in this regard also warrant further research:
1) Does hyponatremia directly induce increased RANK-L activity?
2) What is the intricate relationship between bodily stores of sodium and 
hyponatremia?
5.8.2 – OSTEOCLAST AND OSTEOBLAST ACTIVITY
Hyponatremia and thiazides also appear to induce greater and/or lower osteoclast 
and osteoblast activity, where the relative weights between the two effects warrant 
further study. This also concerns the direct regulation between osteoblasts and 
osteoclasts in an environment of hyponatremia. With thiazide treatment, the works 
of this thesis indicate that short-term therapy increases the risk of fractures, which 
can be speculated to be due to electrolyte disturbances and their effect on postural 
balance. However, long-term therapy appears to decrease fracture risk, speculatively 
due to decreased bone resorption and increased BMD, which was found to be 
borderline positively affected by thiazide therapy. Substantial work both clinical and 
in vitro is needed to further this research topic.
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The initial hypotheses were:
6.1 - PRIMARY HYPOTHESES
1. Hyponatremia is associated with lower BMC and BMD, and a higher risk 
of osteoporosis compared to normonatremia.
2. Thiazide use is protective against fracture occurrence in certain female age 
groups.
6.2 - SECONDARY HYPOTHESES
1. Chronic hyponatremia is associated with worse progression of osteoporosis 
compared to chronic normonatremia.
2. Thiazide use improves BMD compared to none-use.
3. Long-term thiazide use is necessary to obtain a protective effect against 
fracture occurrence.
4. Thiazide use alters urinary excretion of electrolytes in a matter that is 
beneficial to osteoporosis.
5. Hyponatremia is associated with greater comorbidity and economic 
burdens among hospitalized patients.
6. Hyponatremia is predictive of mortality.
6.3 - CONCLUSIONS ON INITIAL HYPOTHESES
1. Hyponatremia and decreases in serum sodium are associated with lower 
BMC and BMD and a higher risk of osteoporosis compared to 
normonatremia in the hip region, not the lumbar spine.
2. Thiazide use was not found to be protective at specific age-groups 
compared to non-use, but age groups of substantially increased risk were 
found compared to non-users.
3. Chronic mild hyponatremia ([Na+] 130-137 mmol/L) is associated with 
lower BMC and BMD at baseline and with worse progression of BMC and 
BMD loss at certain areas of the hip.
4. The combined evidence of existing clinical trials on thiazides and BMD did 
not show a significantly positive effect of thiazide use on BMD 
progression, albeit the changes in BMD were borderline significantly 
positive.
5. Thiazides are associated with progressively lower weekly risk of fracture 
occurrence after long-term use beyond 43 weeks.
6. The combined evidence of existing clinical trials on thiazides and bone 
mineral density show that thiazides form a beneficial pattern of changes in 
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electrolyte concentrations by borderline lowering serum PTH, possibly by 
increased serum calcium.
7. Hyponatremia was not a relatively important predictor of mortality.
8. Hyponatremia is associated with a dose-response relationship between 
lower serum sodium and greater LoS and CoS in hospitalized patients, but 
not with readmission risk as a whole.
6.4 - OVERALL CONCLUSION
Hyponatremia was found to be associated with osteoporosis and worse progression 
of osteoporosis, particularly affecting the hip region. Further prospective study is 
warranted to ascertain this relationship and the possible effects of remedying the 
condition to normonatremia. Even mild hyponatremia ([Na+] 130-137 mmol/L) was 
associated with an increased risk of osteoporosis and osteoporosis progression in 
specific areas of the hip and lumbar spine despite a worse offset, warranting a new 
discussion about therapeutical thresholds and ages to intervene. Thiazides were 
associated with protection against fractures for users as a whole when used 
continuously and long-term beyond 43 weeks, but no systematic age groups with 
beneficial 10-year fracture risks after commencement were found. Thiazides provide 
a pattern of altered electrolyte metabolism that is likely beneficial against 
osteoporosis, but only shows a borderline significantly positive effect on BMD 
directly in current clinical trials. More randomized, controlled trials of thiazides and 





As the first randomized controlled trials of thiazides as antiresorptive agents were 
conducted more than three decades ago, the hypothesis that increased renal 
reabsorption of calcium could prevent deteriorating bone strength is not a novel 
hypothesis of recent years. Despite many clinical trials, thiazides do not figure in 
European or American guidelines of osteoporosis management. This thesis has 
documented a positive pattern of altered electrolyte metabolism when thiazides are 
commenced in a controlled fashion, and the borderline significant, positive effect on 
BMD indicates that one more clinical trial showing beneficial effects could provide 
the final evidence that thiazides affect BMD positively. 
The “BONATHIAD – Bone Association With Thiazide Diuretics” clinical trial 
investigating thiazides’ effect on both BMD, bone architecture, balance and serum 
electrolyte changes over 48 weeks is currently taking place at the Department of 
Endocrinology, Aalborg University Hospital. The study is intended to conclude in 
late 2018 and could provide new information on fracture-predisposing risk factors 
with thiazides and hyponatremia, i.e. balance and physical performance, as well as a 
greater sample size for another systematic review and meta-analysis. 
Provided that BMD improves with thiazide use in a randomized controlled setting, 
this gives an explanation of the many retrospective studies that have found a 
protective role of thiazides on fracture risk. This thesis adds to the understanding of 
this mechanism by showing that prolonged, continuous use for more than 43 weeks 
seems necessary to obtain the protective effect. However, as a substantial sample 
size is necessary in all randomized, clinical trials with fractures as the primary 
endpoint, it would require substantial, multi-center efforts with follow-ups for 
longer than a year to ascertain this evidence in a prospective and controlled matter.
Through the linear relationship between decreasing sodium, lower BMD and more 
burdensome hospitalization, this thesis adds to the understanding that hyponatremia 
even just below the reference interval should call for diagnostic workup and 
therapeutic management. As basal in vitro evidence is present that hyponatremia 
increases bone resorption in a dose-response relationship, an obvious next step is to 
investigate decreases in serum sodium and the effect on the near and long term on 
biochemical markers of bone resorption (e.g. CTX) and bone anabolism (e.g. 
P1NP). As there will be substantial ethical considerations of inducing hyponatremia 
in healthy individuals, a prospective trial should investigate if correcting 
hyponatremia to normonatremia alters bone metabolism, i.e. through the same 
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intertwined and often paradoxical relationship with thiazide diuretics and 
osteoporosis. In retrospective studies, thiazides have been shown to protect against 
osteoporosis-related fractures, but also to cause hyponatremia which is associated 
with a higher risk of falling. In recent years, evidence has been found of an 
association between hyponatremia and osteoporosis in epidemiological and basal in 
vitro studies. Further research is needed to determine three aspects; who will benefit 
from thiazides in terms of fracture risk, why this is the case, and who are running an 
unnecessary risk of thiazide-induced hyponatremia when commencing therapy, 
predisposing to fractures.
The aim of this thesis was to investigate the role of hyponatremia in Danish 
osteoporosis patients, to investigate possible age groups that may benefit from 
thiazide therapy on fracture risk, and to examine the effect of hyponatremia on 
mortality, hospitalization burden and readmission risk.
This thesis is based on six retrospective epidemiological studies using Danish and 
Belgian data of regional and national origins, and one systematic review and meta-








































Hyponatremia, a condition of low serum concentrations of sodium, shares 
an intertwined and often paradoxical relationship with thiazide diuretics and 
osteoporosis. In retrospective studies, thiazides have been shown to protect 
against osteoporosis-related fractures, but also to cause hyponatremia which 
is associated with a higher risk of falling. In recent years, evidence has been 
found of an association between hyponatremia and osteoporosis in epidemi-
ological and basal in vitro studies. Further research is needed to determine 
three aspects; who will benefit from thiazides in terms of fracture risk, why 
this is the case, and who are running an unnecessary risk of thiazide-induced 
hyponatremia when commencing therapy, predisposing to fractures. The aim 
of this thesis was to investigate the role of hyponatremia in Danish osteopo-
rosis patients, to investigate possible age groups that may benefit from thi-
azide therapy on fracture risk, and to examine the effect of hyponatremia on 
mortality, hospitalization burden and readmission risk. This thesis is based 
on six retrospective epidemiological studies using Danish and Belgian data 
of regional and national origins, and one systematic review and metaanal-
ysis reviewing clinical trials of thiazide use on bone mineral density and 
electrolyte metabolism.
